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ABSTRACT
Local Health Departments (LHDs) are critical providers of Human Immunodeficiency Virus (HIV) and
sexually transmitted infection (STI) prevention efforts. HIV Pre-Exposure Prophylaxis (PrEP) is an
evolving public health initiative and practitioners should consider PrEP interventions in context of ethical
decision-making and a broad STI prevention strategy as global incidence of bacterial STIs remains high
and those at-risk for HIV are generally at-risk for other STIs. An evaluation of the Thinking Ethically
framework and LHD PrEP services was performed to fill a gap in the literature and support program
decision-making. A retrospective review of PrEP user medical records from a LHD in north Georgia from
July 2019 to June 2020 was performed and data were assessed using descriptive statistics, negative
binomial, and logistic regression. Total STI tests performed by the LHD from July 2018 to June 2020
were calculated to determine the change in STI testing services associated with the onset of the COVID19 pandemic. The Thinking Ethically framework was valuable to PrEP-related decision-making. There
were 63 PrEP users in the study period of which most were White non-Hispanic (60.3%) men who have
sex with men (61.9%). Retention in care was associated with clinic site. Most bacterial STI cases
diagnosed among PrEP users were asymptomatic (75%). Fifty percent of PrEP users obtained services
beyond STI prevention including vaccination and referrals. District STI testing declined between the
second quarter of 2020 and 2019 with a decline in HIV testing by 38%, syphilis by 48%, gonorrhea and
chlamydia by over 50%. LHD decision-makers can feasibly apply the Thinking Ethically framework to
public health practice. Results support the need for LHD continuous quality management as retention in

care differed by clinic site, and more resources will be needed to engage hard-to-reach populations at-risk
for HIV like injection drug users. The COVID-19 pandemic impacted PrEP and STI services and more
data is needed to determine the long-term effects of the COVID-19 pandemic on the STI landscape.
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CHAPTER 1
BACKGROUND
Statement of the Problem
Local Health Departments (LHDs) are critical providers of population-level Human
Immunodeficiency Virus (HIV) and sexually transmitted infection (STI) prevention efforts and can
significantly impact provision and access to HIV Pre-exposure Prophylaxis (PrEP) services.1 PrEP
is the administration of antiretroviral therapy (ART) combined with behavioral counseling for
primary prevention of HIV.1,2 Public health practitioners should consider multiple ethical principles
to maximize PrEP and STI prevention resources for the greatest population-level benefit in the
context of a broad STI prevention strategy.3,4 Practitioners can elicit consideration of multiple
ethical principles with use of the Thinking Ethically decision-making framework when deliberating
decisions of ethical consequence5 like whether to provide PrEP services or how best to optimize
limited resources. PrEP is an evolving public health initiative and public health practitioners should
weigh factors including biomedical risks, access disparities, and risk behavior with available
resources when implementing PrEP interventions.3,4 However, limited data on LHD PrEP
provision, program impact, and program evaluation is available to guide decision-makers.6 Data
evaluating LHD PrEP intervention outcomes in suburban and rural LHDs in the Southeast US, an
area with significant STI and HIV disease burden, is a current gap in the literature.
HIV incidence in 2018 was 11.4 per 100,000 population (about 40,000 cases per year) in
the United States (US) and disparities in incidence exist.2,7 Total HIV incidence in the US declined
from 2008 to 2018, but incidence has remained steady or increased among racial minorities
including Black and Latino men who have sex with men (MSM).2,7 PrEP has demonstrated
tolerability and effectiveness as HIV prevention when administered as directed with up to 99%
efficacy against sexual transmission of HIV in at-risk groups.2,8 Medications used for PrEP are
generally well-tolerated and adverse events have included gastrointestinal discomfort, nausea,
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decrease in bone mineral density and renal function, hepatitis B flare, and HIV viral resistance.2
Benefits of PrEP have included reduced fear of HIV and feelings of empowerment surrounding
sexual health among PrEP users.9
Public health practitioners should consider PrEP interventions in context of a broad STI
prevention strategy as global incidence of bacterial STIs (gonorrhea, chlamydia, syphilis) remains
high, and those at-risk for HIV are generally at-risk for other STIs.10,11 STI resistance is increasing,
and complications of STIs can include pain, infertility, neurological and cardiovascular disease.10,11
STI prevention strategies should consider behavioral and pathogen-specific factors including social
networks, prevention fatigue, condom use, and probability of transmission as bacterial STI
infection can increase the risk of HIV acquisition.12 Data associating PrEP use with increased risk
behavior has been mixed and increased STI incidence among PrEP cohorts may be attributed to
preexisting increases in STI trends, selection bias, or increased screening which can facilitate
timely diagnosis and treatment.10,11
Public health practitioners must allocate finite resources with consideration to available
resources, cost, risk, and populations most at-risk for HIV.13,14 LHDs at the forefront of the
COVID-19 pandemic response (ongoing at the time of this writing) must also allocate resources to
support existing programs in addition to COVID-19 testing, syndromic surveillance, contact
tracing, and vaccination campaigns. US PrEP-to-need analysis of 2017 fourth-quarter data was
remarkable for disparities between those most at-risk and those receiving PrEP as those at-risk
living in the South and non-Medicaid expansion states were less likely to receive PrEP relative to
need.15 PrEP can be efficient and cost-saving if those most at-risk are prioritized, but allocating
resources for PrEP should be weighed against the impact of enhancing HIV treatment efforts and
the burden of HIV in the target area.13,14 HIV viral control among people living with HIV (PLWH)
through use of ART is considerably effective at reducing the spread of HIV.2 Clinical capacity can
impact the feasibility of proving PrEP as providing condoms requires less clinical capacity than
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oral PrEP, and oral PrEP is expected to require less clinical capacity than future injectable LongActing PrEP (LA PrEP).16 Provider uptake and provision of oral PrEP has been generally slow due
to multiple factors including knowledge, awareness, and stigma.17 High attrition with PrEP use has
also been appreciated.18
Purpose of the Study
The purpose of this study was to perform a program evaluation of LHD PrEP services in
the North Georgia Health District (NGHD) between July 2019 and June 2020. Outcomes included
PrEP user demographics; length of time users are enrolled in the program; diagnosis of HIV,
gonorrhea, chlamydia, syphilis among PrEP users; and description of services provided to PrEP
users beyond STI prevention. The study was framed through the Thinking Ethically framework to
guide future LHD STI prevention efforts and PrEP-related decision-making.
This study also provided a unique opportunity to study LHD PrEP services and STI
testing over the period that included the onset of the COVID-19 pandemic. The COVID-19
pandemic impacted NGHD clinical services during the study period, but this study was not planned
to investigate the impact of COVID-19 on LHD PrEP and STI care. To encourage social
distancing, the NGHD reduced PrEP and STI services and ceased nonessential in-person
encounters for all programs in the second quarter of 2020. Quarterly total of HIV, gonorrhea,
chlamydia, and syphilis tests performed in NGHD clinic sites from July 2017 to June 2020 were
assessed to quantify the degree of NGHD STI service changes associated with the onset of the
COVID-19 pandemic. Assessing total number of performed STI tests from July 2017 to June 2020
served to provide NGHD leadership with baseline data to determine when district STI services
return to pre-pandemic quantity.
Research Questions
1. How can the Thinking Ethically framework be used to inform public health practitioners on
PrEP-related decision-making?
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2. Did NGHD PrEP services reach those most at-risk for HIV in the district?
3. How long did PrEP users stay in the program?
4. What additional services were provided to PrEP users beyond STI prevention?
5. How many asymptomatic bacterial STIs were diagnosed among PrEP users?
6. How much did NGHD STI testing change in the period associated with the onset of the
COVID-19 pandemic?
Delimitations
The study was conducted via a retrospective chart review of NGHD PrEP users between
July 2019 and June 2020, the first year NGHD district-wide PrEP services were provided. Only
those receiving PrEP from the NGHD were included in the study. Those living within the NGHD
but receiving PrEP from providers unaffiliated with the NGHD were excluded. Only those with
STIs diagnosed by NGHD study sites were included in STI assessments. Those living within the
NGHD but diagnosed with STIs by providers unaffiliated with the NGHD were excluded.
Definition of Terms
Antiretroviral Therapy (ART) – medication active against HIV used as prevention among those atrisk and treatment among those living with HIV
HIV Pre-Exposure Prophylaxis (PrEP) – prescribed antiretrovirals for primary prevention of HIV
LHD – Local Health Department
MSM – Men who have sex with men including gay, bisexual, and other men who have sex with
men
North Georgia Health District (NGHD) – a local health district in north Georgia in the southeastern
United States and site of data collection for this study
PLWH – People living with HIV
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PWID – People who use injection drugs
Risk Compensation – increase in behavior that increases risk of STI acquisition due to perceived
protection from HIV due to PrEP use
Sexually Transmitted Infection (STI) – for purpose of this study, STI generally refers to HIV,
gonorrhea, chlamydia, and syphilis
Treatment as Prevention (TasP) – prescribed antiretrovirals for people living with HIV to
effectively prevent HIV transmission through individual and population-level HIV viral
suppression
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CHAPTER 2
LITERATURE REVIEW
Thinking Ethically about HIV
Public health decision-making is complex, and practitioners must consider conflicting
values and ethical considerations when making decisions at the population level.3,19 The field of
public health ethics emerged in the 1990s in response to population-level ethical concerns that
could not be adequately addressed through bioethical principles during the HIV epidemic.19,20
Bioethical principles of autonomy, beneficence, nonmaleficence, and justice are largely focused on
the individual and often used in research and clinical medicine but have been inadequate to fully
address community concerns of individual versus community rights, health promotion, and
resource allocation.19,20 Public health ethics must balance the values of individuals with community
well-being, recognizing that what is in the best interest of the individual is not always in the best
interest of the community.19
The HIV epidemic in the 1990s had a profound impact on public health ethics as medical
providers, policymakers, and public health professionals confronted significant ethical questions
regarding individual versus community rights, allocation of resources, access to care, individual
privacy, and presence of social health disparities.20 Decision-makers were forced to confront social
issues like discrimination, fear and stigma, and balance individual liberty, dignity and health for
those most affected.20 Medical advances surrounding HIV and antiretroviral therapy (ART) have
significantly altered the contemporary public health HIV decision-making landscape, but ethical
dilemmas still exist.3 Public health practitioners must determine how to allocate finite resources to
benefit the most people while striving to reduce health disparities as HIV often impacts vulnerable
and socially disenfranchised groups.3
In 2012, the World Health Organization (WHO) held a multidisciplinary assembly of
international stakeholders including scientists, ethicists, policy-makers, human rights and HIV
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community advocates to discuss the ethical considerations of ART use in HIV prevention.3 ART
use in HIV prevention can be prescribed for people living with HIV (PLWH) as Treatment as
Prevention (TasP) or those of negative HIV status as Pre-Exposure Prophylaxis (PrEP); TasP and
PrEP are both effective prevention strategies.3 The assembly discussed that public health
practitioners will need to use multiple, and potentially conflicting, ethical principles in ART-related
decision-making, and more attention should be provided to social and policy barriers impacting
HIV.3 Decisions will widely vary based on community-level epidemiology, available resources,
and sociopolitical climates as those most at-risk for HIV and sexually transmitted infections (STIs)
are often disenfranchised and face barriers related to the social determinants of health.3 Principles
used in HIV-related decision-making can include utility (prioritizing interventions with the greatest
net benefit), equity (prioritizing interventions that reduce health disparities), urgent need
(prioritizing treatment of the sickest), rule of rescue (prioritizing treatment for those at imminent
risk of death), and prioritarianism (prioritizing the least advantaged).3
In the context of HIV, use of ethical principles in decision-making can yield different
results depending on the frame of reference.3 An intervention chosen using the utility principle can
be perceived to produce the most benefit if it prioritizes PLWH or those of HIV negative status and
if it benefits the largest number of people or those most at-risk, but a strict utility focus on
benefiting the greatest number of people can also result in health disparities.3 Decisions made using
the equity principle are reasonable in principle as it is generally agreed that people should have fair
access to health resources although equity is difficult to achieve in practice due to real-world
resource limitations.3 Furthermore, equity priorities can conflict between prioritizing health status
or health access.3 Principles like urgent need, rule of rescue, and prioritarianism generally prioritize
those of worst health status which conflict with the principle of utility because prioritizing those
most affected can result in fewer resources available for the greater population.3 It can also be
difficult to determine those of worst health or highest-risk in context of HIV because HIV burden is
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closely intertwined with social determinants of health.3 Highest-risk can be interpreted as most atrisk of death from HIV, most at-risk of acquiring HIV, and most vulnerable from low
socioeconomic status.3
HIV-related public health decision-making should generally seek to identify local
priorities to guide fair distribution of resources, maximize population-level benefit, and base
program decisions on data-supported evidence.3 Optimal solutions will vary and must acknowledge
social and political limitations including stigma, discrimination, and illegal nature of some HIVassociated risk factors (like injection drug use or sex work).3 HIV prevention should also be
considered in context of a comprehensive STI prevention strategy due to significant disease
burden, increasing STI incidence, shared prevention strategies and shared risk factors between HIV
and non-HIV STIs.10,11,21
Thinking Ethically is a framework created by Velasquez et al5 at the Markkula Center for
Applied Ethics as a method to identify ethical considerations and apply ethical decision-making to
practice.5 The framework was chosen for its design as an applied framework, stepwise approach to
ethical decision-making, and use of multiple ethical principles which is in accordance with the
WHO recommendation to assess PrEP and HIV prevention from multiple ethical perspectives.3,5
The framework provides a series of steps to gather data and evaluate available options from
multiple ethical approaches to achieve the best course of action.5 After recognizing an ethical issue,
practitioners should gather relevant data about the issue including relevant stakeholders and options
for acting.5 Practitioners should then evaluate each option through the perspective of five different
ethical approaches, the utilitarian, rights, justice, common good, and virtue approach.5
The utilitarian approach emphasizes the action that provides the most benefit and least
harm to all those affected by an action.5 The rights approach emphasizes the moral rights of
individuals which are numerous and have included autonomy, dignity, truth, privacy, and to not be
injured.5 The justice approach emphasizes fairness and equal treatment of those affected by an
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action.5 The common good approach emphasizes community welfare and prioritizes the community
benefit of an action with attention to those most vulnerable and is suited to evaluate policy and
public health.5 The virtue approach emphasizes actions that align with virtuous character traits like
honesty, courage, tolerance, compassion, integrity, prudence and self-control.5 Velasquez et al5
provided a series of questions intended to elicit the perspective of each approach:
•

Which option will produce the most good and do the least harm? (The utilitarian approach)

•

Which option best respects the rights of all who have a stake? (The rights approach)

•

Which option treats people equally or proportionately? (The justice approach)

•

Which option best serves the community as a whole, not just some members? (The
common good approach)

•

Which option leads me to act as the sort of person I want to be? (The virtue approach)5
After working through each question, practitioners should then consider all approaches,

reflect on or hypothetically test the decision, implement the decision, and reflect upon the decision
outcome.5 Velasquez et al5 discussed that ethics is a way people should act and is not a science,
religion, law, cultural norm, or set of feelings.5 There is significant room for debate in ethical
decision-making, but the best action is often identified as ideal through multiple ethical
approaches.5 Thinking Ethically principles (justice, utility, rights, common good, and virtue) were
used to frame the research questions of this study.
STI and HIV Disease Burden
There are over 30 different pathogens known to be sexually transmitted.22 STIs have a
substantial worldwide disease burden and STI incidence has been increasing.11,21,23 The WHO has
estimated that global STI acquisition is over one million cases per day with an annual incidence of
over 350 million cases per year of one of the four common curable STIs (chlamydia, gonorrhea,
syphilis or trichomoniasis).11,22 STI public health practice considerations include newly recognized
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STIs (Zika, hepatitis, Ebola virus), drug resistance (resistant gonorrhea), risk behavior (recreational
drug use, risk compensation associated with antiretroviral success), commercial sex and sexual
violence.21 Generally, bacteria and parasite STIs cause acute symptoms while viral STIs cause
chronic infections.21 STI complications can include infertility, pain, neurological and
cardiovascular complications (syphilis), cancer (human papillomavirus), liver disease (hepatitis A
and B), and death (HIV).11,21,23 Common curable STIs (chlamydia, gonorrhea, and syphilis) are
often asymptomatic leading to delayed screening, diagnosis and treatment.21–23 STI related tissue
impairment also increases risk of HIV acquisition.11,21–23
Those most at-risk for STIs and HIV in the US include those living in southern states,
youth, MSM, racial minorities and those of low socioeconomic status.7,23 US STI incidence has
been increasing, and youth age 15 to 24 years accounted for about half of STI diagnosis in 2018.23
From 2017 to 2018, chlamydia, gonorrhea and syphilis incidence increased among males and
females of all ethnic groups in all regions of the US.23 In 2018, chlamydia was the most reported
notifiable infectious disease with a disease burden of 539.3 cases per 100,000 population, a 2.9%
increase from 2017.23 Gonorrhea was the second most reported notifiable infectious disease with a
5% increase from 2017. Syphilis incidence was 115,045, the highest since 1991 and a 13.3%
increase from 2017.23 In 2018, primary and secondary (P&S) syphilis were predominantly
identified among MSM (53.5%), PLWH (41.6%), and women (14.2%).23 Women are an emerging
risk-group for syphilis; from 2017 to 2018, a 30.4% increase in P&S syphilis incidence was
appreciated among women which is concerning for maternal transmission and congenital syphilis.23
In 2018, incidence of chlamydia and gonorrhea was highest among US states in the South, and
incidence of syphilis was highest among states in the West followed by states in the South.23
Global HIV mortality and morbidity have made significant advances since the 1990s.24
Global HIV mortality peaked in 2004-2005 with over two million deaths worldwide and declined
to 1.1 million deaths in 2015.24 HIV incidence peaked in 1997 with an estimated 3.5 million
infections per year and declined to 2.1 million in 2015.24 Global HIV prevalence has also declined
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since 2001, and study of prevalence must take into account that PLWH are now living longer due
to advances in ART efficacy, tolerability, and access.24
The impact of advances in ART efficacy, tolerability, and access on global HIV mortality
and incidence are considered significant public health successes.24,25 Trends in life expectancy of
PLWH have increased in all parts of the globe although disparities in access to HIV testing and
treatment still exist and high-income countries have appreciated the most gain.25 In 2012, the life
expectancy of PLWH in Canada was about 90% of those of negative HIV status while the life
expectancy of PLWH in Rwanda was about 60% of those of negative HIV status.24,25 In Canada,
the life expectancy of a 20-year-old living with HIV compared to those of negative HIV status
increased from 50.7% in 2000-2003 to 89.1% in 2008-2012.25 PLWH who continue ART and
maintain HIV viral suppression also have virtually no risk of transmitting HIV to others (Treatment
as Prevention).26 The current Joint United Nations Programme on HIV/AIDS (UNAIDS) global
ending HIV epidemic campaign, 90-90-90, targets for 90% of PLWH to know their status, 90% of
those to receive sustained ART, and 90% of those to achieve sustained HIV viral suppression.24
The current US Department of Health and Human Services (HHS) ending the HIV epidemic
campaign, Ending the HIV Epidemic: A Plan for America, targets a 75% reduction in new HIV
infections by 2025 and 90% reduction by 2030 through sustained HIV viral suppression among
90% of PLWH in the US and prevention strategies including PrEP and syringe services programs
for people who use injection drugs (PWID).27
In the US, PLWH are generally older while populations most at-risk for new diagnosis
include youth, MSM, PWID, racial minorities, those of low socioeconomic status and in southern
states.7 In 2017, there were 1,003,782 known PLWH in the US with a prevalence rate of 308.7.7
Those aged 50-54 (767.8) were the largest group of PLWH followed by 55-59 (660.6).7 Rates of
new HIV diagnoses have generally declined since 2013 however disparities among at-risk groups
exist and incidence has increased among some sub-populations.2,7 In 2018, the age group with the
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highest HIV incidence was among those 25 to 29 years (32.5) followed by 20-24 years (27.6).7
HIV incidence by race was highest among Black/African American (39.3) followed by
Hispanic/Latino (16.2).7 In 2018, males accounted for 81% of diagnoses and the most significant
risk factors were MSM (70%) followed by PWID.7 South US states continued to have the highest
incidence (15.7) compared to the Northeast (10.0), West (9.3), and Midwest (7.2).7
In 2017, Georgia ranked first among US states in HIV incidence among adults and
adolescents and fourth in HIV prevalence.28 At-risk groups for HIV in Georgia mirror those of the
US with Black/Non-Hispanic, youth and MSM at highest risk.28 The North Georgia Health District
(NGHD), a largely suburban and rural area, includes two counties identified among the 220 most
vulnerable counties in the US for rapid transmission of HIV and hepatitis C due to injection drug
use in a 2016 assessment by the Centers for Disease Control and Prevention (CDC).29,30 In 2017,
NGHD youth had the highest incidence of HIV and PLWH were generally older, which is
consistent with the state and national profile, but racial and ethnic group HIV incidence and
prevalence differed from the state and national data as most PLWH in the NGHD were White/NonHispanic.28 In 2017, NGHD HIV incidence was largest among White/Non-Hispanic (50%)
followed by Hispanic (21.4%), and Black/Non-Hispanic (17.9%) with the largest number of new
diagnosis occurring among youth age 20-29 (39.3%).28 In 2017, PLWH in the NGHD were largely
White/Non-Hispanic (57.2%) followed by Black/Non-Hispanic (19.4%) and Hispanic (15.7%), and
predominantly adults age 30-39 (18.9%), 40-49 (24.8%), and 50-59 (29.2%).28
Structural Factors Associated with STI Risk
The HIV and STI epidemic is well-established as interwoven with social determinants of
health: genetic and individual factors alone cannot account for the significant discrepancy in HIV
and STI risk among low income and minority populations.31,32 Multiple studies assessing HIV and
syndemic risk (accumulated risk of two or more factors that work synergistically) with intersecting
negative social, behavioral, and structural factors have been performed.33 Those most at-risk for
STIs (youth, racial and ethnic minorities, people of low socioeconomic status, MSM, and PWID)
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often face multiple syndemic risk factors, and global and national prevention efforts have
emphasized the importance of targeting social determinants of health in HIV prevention since the
1990s.31–34 Syndemic HIV and STI risk factors have included social instability, homelessness,
unemployment, low education level, poverty, stigma, discrimination, trauma, incarceration, drug
use, geographic location and limited healthcare access.31,33,34
A cross-sectional and longitudinal analysis comparing gonorrhea incidence to
socioeconomic status by decennial census tract (1990 and 2000) in New York state (excluding New
York City) between 1992-1993 and 2001-2002 found geographic associations between areas of low
socioeconomic status and gonorrhea incidence, and changes in gonorrhea incidence were
associated with changes in socioeconomic status.35 Study modeling demonstrated that a 5%
increase in census tract poverty rate was associated with an 8% increase in gonorrhea incidence
(relative risk 1.08).35 Multivariate modeling of census tract, gonorrhea incidence, and race were
remarkable for increased gonorrhea incidence disparities among non-Hispanic Blacks in areas
where non-Hispanic Blacks were less than 10% of the population.35 In areas with less than 10%
non-Hispanic Blacks, a 5% change in poverty rate was associated with a 23% increase in gonorrhea
incidence among Black residents compared to areas with over 10% non-Hispanic Blacks where a
significant change in gonorrhea incidence was not appreciated.35
Minority populations in the US, like Black and Latinos, encounter disparities in virtually
all social determinants of health including poverty, racism, trauma, incarceration, and substance
use compared to Whites.33 According to the 2010 US census, Blacks had the highest rate of poverty
followed by Hispanics and Whites.33 Blacks and Latinos have been more likely to experience
individual and systematic racism compared to Whites including residential segregation,
environmental health stress, community violence, criminal justice discrimination, and live in a
resource-poor area.33 MSM, bisexual, and transgender individuals have faced additional stress of
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homophobia and gender-related stigma or abuse which increases the risk of depression and
condomless sex.33,36
Systematic racism and stigma limit the social and political capital of minority communities
and increase the risk of psychological conditions and sexual risk behavior that subsequently
increase the risk of HIV, particularly among minority youth and transgender individuals.33,36
Research on HIV risk, childhood and adolescent sexual abuse and trauma (a known risk factor for
increased risk behavior and condomless sex) since the 1990s has demonstrated higher rates of
sexual and physical abuse among Black and Hispanic MSM compared to Whites.33 In 2003, US
Blacks were more likely to be incarcerated (1 in 8) compared to Latinos (1 in 27) and Whites (1 in
63).33 Racial and ethnic minorities have also been more likely to experience substance abuse
disorders, initiate injection drug use in adolescence, experience addiction, relapse after substance
use treatment, and receive less substance use treatment compared to Whites.33
Illicit Drug Use and STI Risk
Illicit drug use has been increasing in the US and is strongly associated with high-risk
sexual behavior including multiple partners and condomless sex.37 Opioids include drugs like
prescription opioids, heroin, synthetic and illicitly manufactured opioids (like illicitly manufactured
fentanyl).37,38 In 2017, 67.8% of the 70,237 drug overdose deaths in the US were opioid-related and
the number of synthetic opioid-related deaths in the US increased by 45.2% from 2016 to 2017.38 A
recent cross-sectional community-based survey study investigating the intersection between
lifetime STI diagnosis, illicit drug and opioid use in Alachua County, Florida (a county with STI
rates higher than the state and national average) found that 204 (9.3%) of 2,194 survey respondents
age 18 to 50 years self-reported ever having an STI, of which, 74.2% reported any illicit drug use,
69.6% reported marijuana use, and 52.5% reported opioid use.37 Those self-reporting an STI were
also more likely to be female, food-insecure within the last 12 months, unmarried and with less
education.37
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STI prevention programs that include content on alcohol and illicit drug use have
demonstrated greater efficacy compared to those without alcohol and illicit drug content.39 A
cluster randomized clinical trial comparing the impact of STI prevention programs with content on
sexual risk reduction only; sexual risk reduction and alcohol; and sexual risk reduction, alcohol,
and marijuana on STI incidence at 12-months after completion of the STI prevention program
found the lowest STI incidence among those in the sexual risk reduction, alcohol and marijuana
group.39 The study included 460 adolescents at an adolescent detention center from 2010 to 2014,
of which 361 presented for a 12-month follow-up.39 At 12 month follow-up, 3.9% of the sexual risk
reduction, alcohol and marijuana group; 10.2% of the sexual risk reduction and alcohol group; and
12.4% of the sexual risk reduction group were diagnosed with an STI of which chlamydia (79.6%)
and gonorrhea (13.6%) were the most common.39
STI prevention efforts among drug users should be tailored to the population as
differences in HIV risk behavior by gender and drug use have been appreciated although data on
gender-based differences in number of partners, condomless sex, and sex exchange among drug
users has been mixed.40 A survey assessing gender-based HIV risk among 1,429 drug users in
multisite drug treatment programs across the US in 2007 was remarkable for overall increased
sexual behavior risk among women drug users compared to men.40 Women were more likely to
have multiple partners (20% versus 13%) and no gender difference in unprotected sex or sex
exchange was appreciated.40 Men were more likely to use injection drugs (32% versus 24%) and no
gender difference in needle sharing was appreciated.40 Women who used alcohol were 1.11 times
more likely to have risky sex behavior compared to men.40 Women who had greater psychiatric
comorbidities were 1.14 times more likely to engage in risky sex behavior compared to men.40
Participants (male and female) who used stimulant illicit drugs were 1.57 times more likely to
engage in risky sex behavior than those who did not use stimulants.40 Participants (male and

22
female) who reported history of sexual abuse were 4.1 times more likely to engage in risky sex
behavior compared to those without history of sexual abuse.40
Crisis and STI Risk
The 2020 COVID-19 pandemic is a significant factor impacting data collected in this study
as global social distancing drastically changed global economic and social behavior during this
study period. It was assumed that STI incidence during the pandemic declined due to reduced
screening (the study sites postponed or limited PrEP and STI care during the COVID-19 pandemic)
or due to an actual reduction in incidence related to social distancing. The long-term effects of
COVID-19 on mental health, economics, and STI incidence are not yet known, and this study
provided a unique assessment of LHD STI incidence surrounding a global pandemic in the
Southeast US. Previous data has supported increased STI incidence and STI-associated risk
behavior surrounding periods of political, environmental, and socioeconomic crisis like the
September 11, 2001 attack and the 2008 Financial Crisis.41–44
A retrospective chart review of 3,520 PrEP users from January and April 2020 in Boston,
Massachusetts to assess the impact of COVID-19 on PrEP care found the number of clients
initiating PrEP fell by 72% (from 122 per month in January to 34 per month in April 2020).45 The
number of PrEP prescription refill lapses increased (140 in January to 407 in April) with youth,
racial minorities, and those with public versus private insurance more likely to have a lapse in PrEP
refill.45 Screening for gonorrhea and chlamydia also declined by 85% between January and April.45
A separate internet survey of 1,051 MSM in the United States to investigate the impact of COVID19 on sexual health in April 2020 found that 51.3% reported fewer sex partners during the COVID19 pandemic, 47.6% reported no change in number of sex partners, and 0.9% reported increased
number of sex partners, 92.9% reported no change in condom use, and 68% reported reduced
opportunities to have sex.46 When asked about adherence to local COVID-19 social distancing
stay-at-home orders, 20.1% reported 100% adherence, 71.4% reported between 50% and 100%
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adherence, and 8.5% reported less than 50% adherence. When asked about life impact, 19.1%
reported losing their job, 72.7% reported increased anxiety, 14.8% reported being food insecure
within the last 12 months, 9.9% reported increased use of recreational drugs, and 26% reported
increased use of alcohol.46
A 2002 internet survey of 2,915 MSM investigating sex and drug behavior three months
before and after the September 11 attack found that drinking until drunk, condomless anal sex, and
number of partners increased among those who reported death of a family member or friend in the
attack (n=329) compared to those reporting seeing the attack in person (n=104) or living within a
10 mile radius of the World Trade Center or Pentagon (n=35).41 Participants reported similar levels
of drinking until drunk, condomless sex, and number of partners before the attack.41 After the
attack, the adjusted odds ratio of drinking until drunk, increased condomless sex, and increased
number of partners among those reporting a death was 1.41, 1.44, and 1.94; witnessing the attack in
person was 1.04, 1.14, and 0.74; and living within 10 miles of the attack site was 0.87, 0.73, and
1.72 respectively.41
A survey of Manhattan residents in New York found that cigarette, alcohol and marijuana
use were increased at one (n=988) and six months (n=854) after the September 11 attack.42 At six
months, average reported consumption of cigarettes increased by 103.8 cigarettes per month
(median of 30), alcohol increased by 17.7 drinks per month (median of 9), and occurrence of
marijuana use increased by 7.6 incidents per month (median of 2).42 Survey respondents who
reported psychological or posttraumatic stress symptoms were more likely to report increased
substance use, and a reduction of psychological stress symptoms at six months was not associated
with a reduction in drug use.42 The authors discussed that the addictiveness of drugs may prolong
changes in drug use beyond the initial stress response to a traumatic event.42
A study assessing adherence to HIV treatment among MSM enrolled in the Protease
Inhibitor Longitudinal Life Study (ongoing in the time surrounding the September 11 attack) found
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a significant increase in missed or suboptimal ART doses immediately following the September 11
attack.47 Of 300 study participants, 68 were found to have sufficient adherence data before and after
the attack.47 In a 14-day period, the cohort missed an average of 2.67 ART doses before and 5.07
ART doses after the attack and reported late ART administration (four or more hours off schedule)
an average of 2.34 doses before and 4.34 doses after the attack.47 ART adherence is essential to
HIV TasP and suboptimal ART adherence can increase the risk of HIV transmission.26
Data has also demonstrated increased infectious disease and STI incidence during
economic crisis as periods of individual stress can increase high-risk behavior and reduced
spending often leads to fewer available resources for disease prevention, screening, and
treatment.43,44 Areas of Eastern Europe and the former Soviet Union experienced a severe economic
crisis in the 1990s as average gross domestic product fell by about one-third, and rates of HIV and
Tuberculosis increased during that time (Tuberculosis incidence almost tripled in Russia).44
Increases in disease burden outlasted the economic crisis and some areas of eastern Europe and the
former Soviet Union were unable to reverse or halt the spread of HIV and Tuberculosis over a
decade later.44 A systematic review of 37 studies on the impact of economic crisis on infectious
disease found 30 studies that identified worsening disease outcomes during periods of crisis, and
few studies identified positive outcomes including healthcare reform triggered by deteriorating
disease control during the economic crisis.44 A study assessing STI diagnosis during the 2008
global financial crisis via retrospective review of 1,437 medical records in an STI treatment clinic
in Granada, Spain demonstrated an increase in STI diagnoses from 56.6% in the non-crisis period
(2000-2007) to 75.2% in the crisis period (2008-2014).43 STIs diagnosed in the crisis and non-crisis
periods were human papillomavirus (n=103 and 69), candida (n=22 and 37), molluscum
contagiosum (n=18 and 14), gardnerella (n=13 and 8), syphilis (n=13 and 10), gonorrhea (n=12 and
10), HIV (n=6 and 5), and trichomoniasis (n=1 and 3).43
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Protective Factors Reducing STI Risk
Protective factors against HIV and STI acquisition can be social, behavioral, and
structural.33,34 Reduced HIV risk has been associated with structural factors like the availability of
social welfare programs for finance, education, housing, and medical assistance; community
factors like neighborhood cohesion and social capital; and individual psychological resilience like
adaptive coping, empowerment, and self-efficacy.33 National and community public health
interventions in the US have generally attempted to reduce structural health disparities with policy,
legal action, and funding through initiatives like social welfare programs, legal action against
discrimination, and appropriation of funding to community organizations working to improve
economic and educational disparities.32,33 An ecological study of 66 metropolitan areas in the US
from 2003 to 2015 found lower rates of STIs among women in states with higher minimum wage.48
A one-dollar adjusted increase in minimum wage was associated with a 19.7% decrease in syphilis
and 8.5% decrease in gonorrhea among women.48 Minimum wage increase was not associated with
a change in chlamydia rates.48 Confounding variables and limitations in this study exist; however,
data has supported that presence or absence of social welfare policies are associated with
population STI risk.48
At the individual level, condoms remain the primary public health prevention strategy
against multiple STIs with well documented clinical and cost-effectiveness.49–51 Condom nonuse is
the most significant risk factor for STI acquisition, and condoms have demonstrated low failure
(breakage or slippage) rates in vaginal and anal sex.49–51 STI acquisition risk also depends on
number of exposures, disease-specific infectivity, and probability of condom failure.49 Condoms
are more likely to be effective in preventing STIs transmitted through body fluids (HIV, chlamydia,
and gonorrhea) than direct skin contact (syphilis) and disease-specific condom effectiveness has
been appreciated.49 With condom use in vaginal intercourse, gonorrhea infectivity has been
estimated at about 0.20 in men and 0.50 in women, syphilis infectivity has been estimated at about
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0.30, and average HIV infectivity has been estimated to be about 0.001.49 HIV infectivity is
variable depending on an individual’s HIV viral load and low estimated average HIV infectivity
has been attributed to lower transmission risk among those adherent to ART with suppressed HIV
(Treatment as Prevention).49
Numerous studies regarding sexual behavior and condom use were collected in the 1990s
and data from this time strongly supported the use of condom subsidies to increase condom uptake
after cost was determined to be a significant barrier to condom acquisition in the US.52 A 1999
study comparing condom uptake and longitudinal survey data during a state-wide free condom
distribution campaign and reduced cost (25 cents) condom distribution campaign in Louisiana
found that condom distribution significantly declined when the price of condoms increased from
free to 25 cents.52 In the state-wide free condom campaign, condoms were distributed to statefunded health clinics and over 1,000 businesses in areas with high rates of STIs including
convenience stores, salons, motels, and liquor stores with an average of 200,381 condoms
distributed per month state-wide.52 After condom cost increased from free to 25 cents, state-wide
condom distribution reduced to 2% of the free condom volume with an average of 4,217 condoms
distributed per month.52 Consumers at 195 of the businesses receiving free condoms were surveyed
on condom uptake and use when condoms were free (time 1), three months after condom price
increased to 25 cents (time 2), and nine months after the first survey (time 3).52 Survey data
demonstrated a reduction in condom uptake after the price of condoms increased.52 When condoms
were free (time 1), 57% reported obtaining condoms of which 77% used condoms during their
most recent sexual encounter.52 When condoms were 25 cents (time 3), 30% reported obtaining
condoms of which 64% used condoms during their most recent sexual encounter.52
A meta-analysis of structural condom interventions from 1998-2007 found that condom
uptake was increased through interventions that improved condom accessibility and availability
among multiple high-risk groups.53 Effective interventions included free condom distribution,
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social marketing to increase condom use, and improving in-store condom visibility.53 A recent
assessment of retail barriers to purchasing condoms in Atlanta, Georgia, an urban area in the
Southeast US at high-risk for STIs, found that environmental and physical barriers to purchasing
condoms exist.54 Few stores sold condoms relative to population in the most populated areas of the
city (one store per about 7,000 people), 80% of stores required interaction with retail associates to
access condoms, and 28% of stores kept condoms out of sight below the checkout counter.54 The
authors discussed that at-risk populations may experience embarrassment requesting assistance
from retail clerks when purchasing condoms, and environmental changes to increase condom
uptake can include improved retail visibility, installation of condom vending machines, selfcheckout, and online ordering.54
Sexual Risk Behavior and Behavior Change
A significant body of literature on risk behavior and HIV prevention has been developed
since the 1980s, and behavior modification and condom use were the foundation of HIV prevention
for the first 30 years of the HIV epidemic before significant biomedical advances like TasP and
PrEP were available.14,55 HIV and STI prevention behavior modification interventions are typically
founded in social science behavior change theory like theory of reasoned action, theory of planned
behavior, and social cognitive theory and generally attempt to reduce individual risk-taking
behavior (reduced condomless sex, number of sex partners, drug use or needle sharing) by
modifying a risk factor or determinant.55,56 Risk determinants are numerous and have included
individual and systematic factors.56 Individual risk determinants and have included attitude,
knowledge, self-efficacy, depression, childhood abuse, substance use, interpersonal and behavioral
skills, perception of risk and HIV severity, and perception that behavior change is feasible,
desirable and controlled by the individual.55,56 Systematic factors associated with sexual risk
behavior have included discrimination, cultural norms, and socioeconomic status.55,56
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A meta-analysis of 194 HIV-related behavior change interventions from 1985 to 2003
found that interventions that focused on attitude, education, behavior and interpersonal skills were
most effective, and interventions that encouraged active participation (like role-playing condom
negotiation and client-centered counseling) were more effective than those using only passive
techniques (like watching educational videos).55 Intervention impact depended on participant
characteristics including age, gender, risk group, ethnicity, and past condom use.55 Youth were
more impacted by normative social pressure, men often had more control on condom use than
women, and interventions with MSM were generally more effective than those with women or
PWID.55 Interventions based on the information-motivation-behavioral skills model attempted to
change social norms, perceptions of behavioral control and vulnerability to HIV, and were effective
only when paired with behavior skills training (like carrying condoms and negotiating condom use
with partners).55 Fear-based interventions were less successful than interventions based on
motivational and cognitive empowerment and could be counter-productive.55
Individual sexual behavior has also been considered complex to study due to the intimate
nature of sex, involvement of another individual, and presence of multiple associated individual
and systematic factors that can be difficult or unethical to control with experimental study design.56
A systematic review assessing longitudinal and experimental studies on HIV prevention, sexual
risk behavior and psychosocial variables from 1991 to 2014 found that temporal data on
associations between sexual risk behavior and behavior risk determinants have been mixed.56
Among 44 longitudinal studies, 44.3% assessed sexual risk behavior of MSM, and the most
consistent factors with a longitudinal association on condomless sex were depression, substance
use, childhood sexual abuse, and having a previously diagnosed STI although the direction of
correlation was mixed.56 Among nine experimental studies, experiment induced changes in selfefficacy, sex norms and expectations had mixed results on behavior change.56 Experiment induced
changes in knowledge had no significant effect.56 The authors discussed that theoretical and
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associated sexual behavior risk factors are significant despite a lack of experimental data due to the
complexity of assessing sexual behavior as some factors (like sexual abuse or discrimination)
cannot ethically be induced in a controlled experimental setting.56
Most data on sexual behavior change and STI incidence among PrEP users have been
collected in clinical trial or open-label settings, like iPrEX, iPERGAY and the PROUD trial.10,57
Data demonstrating increased STI incidence among PrEP users has been largely consistent, data on
presence of behavior change has been mixed, and data collected in clinical trial or open-label
settings and may not be generalizable to community-based settings.10,57 A longitudinal cohort study
assessing sexual behavior and condom use among 183 MSM PrEP users in a public health
community-based STI clinic in Seattle, Washington from October 2014 to April 2017 found that
the number of condomless sexual encounters increased and about half of PrEP users were
diagnosed with a bacterial STI during the first year of PrEP use.57 In this cohort, 13.8% reported
condomless sex before starting PrEP, 22% reported condomless sex at nine months of PrEP use,
and 16% reported condomless sex at 12 months of PrEP use.57 The average STI diagnosed per
person was 0.5 before starting PrEP and 1.1 in the first year after starting PrEP although it is not
clear if this increase in STI incidence was due to behavior change or increased screening.57 Number
of partners, number of partners living with HIV, and sexual position (insertive or receptive) did not
significantly change throughout the first year.57
A study of community-based PrEP users in the community-based Kaiser medical system in
San Francisco from 2012 to 2015 assessed STI incidence among 657 PrEP users and behavior
change among 143 survey respondents.58 The study included 388 person-years of PrEP use and the
average length of PrEP use was 7.2 months.58 No new HIV diagnoses were appreciated among 657
PrEP users during the study period, 30% were diagnosed with a non-HIV STI within the first six
months, and 50% were diagnosed with a non-HIV STI within the first 12 months.58 In this cohort,
143 PrEP users completed a survey on sexual behavior with 76% reporting no change in number of
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sex partners, 56% reporting no change in condom use, and 41% reporting decreased condom use.58
The researchers were unable to identify factors associated with increased number of partners or
reduced condom use and considered no new HIV diagnosis to be significant.58 The researchers
estimated that, in absence of PrEP, HIV incidence in this population would have been as high as
8.9 per 100 person-years based on data from a previously performed delayed-PrEP study arm with
similar STI incidence.58
A study assessing bacterial STI incidence of 280 PrEP users at an outpatient center in New
York by screening for bacterial STIs at 3-month intervals instead of 6-months intervals as
recommended by current CDC clinical PrEP guidelines found 21% of PrEP users were diagnosed
with a bacterial STI within the 6 months before starting PrEP, 11% were diagnosed on their initial
PrEP visit, 13% were diagnosed at 3-month follow-up, and 15% were diagnosed at 9-month
follow-up.59 Ten percent of all bacterial STIs diagnosed in the study period were asymptomatic and
identified by routine STI screening, 77% of those diagnosed at 3-month screening and 68% of
those diagnosed at 9-month screening were asymptomatic.59 The authors discussed that 24% of the
cohort would have had delayed bacterial STI diagnosis and treatment if 3-month screening had not
been performed, and more frequent STI screening may benefit timely bacterial STI diagnosis and
treatment.59
Behavior Risk Optimism and Risk Compensation
Studies in the 1990s and 2000s on risk optimism, an optimistic feeling about HIV risk due
to advances in HIV treatment, and increases in sexual risk behavior demonstrated consistent
associations between risk perceptions and behavior.56,60 Most data from that time attributed
increased sexual risk behavior to risk optimism although one cross-sectional and longitudinal study
using survey data of MSM age 18 to 27 from 1998/1999 (n=538) and 2000/2001 (n=275) found
that HIV treatment optimism did not predict risk behavior but risk behavior did predict HIV
treatment optimism.60 These results were inconsistent with the mainstream assumption of
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perception-behavior temporality.60 The researchers suggested that HIV treatment optimism may be
a rationalization after participation in condomless sex or risky sexual behavior and discussed the
need for additional study to determine causality.60 Furthermore, confounding variables that could
increase sexual risk behavior at that time included emerging personal use of the internet and
recreational drugs like amphetamines and sildenafil (brand name Viagra), released in 1998.60
Contemporary STI-associated sexual risk behaviors are consistent with those over the last 30 years
and include internet use with mobile dating apps and recreational drug use associated with
addiction or mental health conditions like anxiety or depression.21
Risk compensation, an increase in risky sexual behavior due to perceived protection, was
historically credited for increased STI incidence among women after the advent of oral
contraceptives and in the 1990s among those presenting for HIV care.61 Risk compensation in the
context of PrEP is generally defined as a change in behavior that increases risk of STIs due to
perceived protection from HIV including reduced condom use or increase in number of sex
partners.10,21,57 Data attributing PrEP user STI incidence increase to risk compensation has been
mixed.10 Risk compensation has been used by some providers and decision-makers to explain a
global increase in non-HIV STI incidence and justify withholding PrEP.21,62 Conversely, others
have disputed the significance of risk compensation in global STI incidence trends arguing that
PrEP-eligible individuals are generally considered to be at higher risk for STIs and increases in STI
incidence can be attributed to selection bias, preexisting trends, or increased STI screening among
PrEP users compared to non-users.10,61,62 PrEP advocates argue that an association between PrEP
and behavior change does not undermine the impact of PrEP on HIV prevention, and support PrEP
as a part of a comprehensive STI prevention strategy that includes sexual behavior risk
counseling.62
Qualitative interviews of 14 PrEP using MSM in Seattle, Washington found that
commonly stated reasons for not using condoms were perceptions that condoms reduced
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spontaneity, were awkward to use, reduced physical sensation, and reduced intimacy.63 Many
respondents perceived PrEP as a safety measure to offset a preference for condomless sex or selfrecognized pattern of condomless sex behavior despite an intention to use condoms.63 Qualitative
interviews with 30 PrEP using MSM in San Francisco, California revealed reduced condom use
among 73% of respondents, 40% continued to use condoms with new partners, 16.7% reduced
condom use with partners who were also taking PrEP, and 13.3% reported condomless sex after
starting PrEP and resumed condom use after being diagnosed with a non-HIV STI.64 Participants
also reported reduced condom use due to feeling protected from HIV or during periods of drug use
that altered decision-making.64 In the Seattle and San Francisco study, respondents who
consistently used condoms reported fear of non-HIV STIs as reason for continued condom use.63,64
HIV and STI Prevention by Abstinence
Abstinence from sexual behavior is a clear way to prevent STIs, but abstinence education
as a public health strategy has been ineffective at preventing STIs and teenage pregnancy despite
support from the US federal government and many US states.65 Two systematic reviews performed
by the Community Preventative Service Taskforce, a nonfederal body that provides data to inform
public health policy and decision-making in the US, found insufficient evidence to support
abstinence education programs, and sufficient evidence to support comprehensive sexual riskreduction education as a public health strategy to reduce sexual risk behavior and prevent
pregnancy and STIs among middle and high school-age adolescents.66 A comparison of US state
school sex education policies in 2005 found that states with policies emphasizing abstinence
education had worse teenage pregnancy rates compared to those providing education on abstinence,
contraception, and condom use.65 States placing more emphasis on abstinence were also more
likely to have residents living in poverty and higher degree of religiosity than those with more
comprehensive sex education programs.65
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HIV Prevention by Treatment as Prevention
Treatment as Prevention (TasP) is a strategy to reduce HIV transmission through early
initiation and consistent use of ART by PLWH.26,67–69 TasP is effective to prevent HIV by
suppressing HIV viral replication in sites of HIV transmission including blood, tissues and
secretions of the genital tract.26 A landmark study in 2011, HTPN052, demonstrated that early ART
initiation reduced HIV transmission among serodiscordant couples (one negative partner and one
partner living with HIV) by 96%.26,67–69 This scientific breakthrough led to a change in global HIV
treatment and prevention strategies to initiate ART among all PLWH regardless of CD4 and
immune status.26,69 Subsequent TasP studies (PARTNER, Opposites Attract, and PARTNER2)
demonstrated even superior results.68 The current US Health and Human Services core HIV
prevention message states People Living With HIV who are undetectable or virally suppressed
have effectively no risk of spreading HIV to their HIV negative sexual partners.68 Current global
HIV treatment and prevention strategies emphasize the importance of TasP along with other
prevention measures including behavior modification, condom use, and PrEP.69
ART tolerability and availability have significantly improved since the completion of the
first triple-drug therapy studies in 1996.24 Reduced global HIV incidence has coincided with global
scale-up of ART provision and access throughout the 2010s.26 In 2010, WHO guidelines reserved
ART for those with late-stage HIV (CD4 less than 350 cells/mm3), landmark studies demonstrating
improved HIV treatment outcomes and TasP with earlier ART initiation were completed shortly
after (HTPN052 TasP study in 2011), and WHO guidelines changed to support universal ART
(providing ART to every PLWH regardless of CD4 count) by 2016.26,67
PLWH must maintain consistent ART use to sustain HIV viral suppression, and ART
should be initiated early in HIV infection for optimal TasP as people with acute or early HIV
infection have been estimated to be over 20 times more likely to transmit HIV than those with
established infection.26 Those with acute HIV (two to four weeks after infection) are known to have
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the highest HIV viral load (amount of circulating HIV) increasing risk of HIV transmission.70 After
the acute phase, HIV viral load declines and gradually increases over time in absence of ART
(chronic HIV infection).70 End-stage HIV occurs after about 10 years in absence of ART; is
characterized by CD4 below 200 cells/mm3, presence of opportunistic infection, and high HIV viral
load that again increases the risk of HIV transmission.70 Data on the long-term impact of acute HIV
infection on population-level incidence has been mixed and PLWH of all stages can transmit HIV
without consistent ART use.26,70
Supporting ART adherence is essential for optimal HIV treatment outcomes, HIV
suppression (HIV viral load below 200 copies of viral RNA per mL of serum) and TasP.26,68,71 In
2015, CDC national HIV surveillance estimated that 60% of all PLWH in the US were virally
suppressed, 80% of PLWH engaged in HIV treatment were virally suppressed, and two of three
PLWH sustained HIV viral suppression for one year.68 In the US, the Health Resources and Service
Administration’s (HRSA) public health Ryan White HIV/AIDS Program has provided treatment
and support services to over 50% of PLWH in the US and uses a variety of social support services
in attempt to reduce treatment disparities.71 In the US, disparities in ART access, adherence and
TasP remain among youth, Blacks, women, transgender, and housing insecure populations.71 From
2010 to 2016, national Ryan White HIV/AIDS Program HIV viral suppression increased from
69.5% to 84.9% among all clients.71 Disparities in HIV viral suppression also declined from 2010
to 2016 between Black and White clients (13% to 8.1%), male and transgender clients (9% to 6%),
male and female clients (5% to 1%), and those age 13 to 24 (youth) and 55 to 64 (33% to 20%).71
Continued reduction of ART disparities is essential to ending the HIV epidemic.71
HIV Prevention by HIV Pre-Exposure Prophylaxis
ART use for PrEP in the US was FDA approved in July 2012 and provides an opportunity
for at-risk groups to engage in clinical care, receive risk-reduction counseling and STI screening.2,61
PrEP is recommended for sexually active individuals at-risk for HIV including those who are not in
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a monogamous relationship with an HIV negative partner, those with recent STI diagnosis, and
PWID.2 Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC, brand name Truvada) and
tenofovir alafenamide/emtricitabine (TAF/FTC, brand name Descovy), a combination of two
nucleoside reverse transcriptase inhibitors, are the predominant medications used for PrEP in the
US and are up to 99% effective at preventing HIV through sexual transmission when taken daily as
directed.2,72,73 Event-driven (on-demand or 2-1-1 PrEP) is the use of PrEP on days of and
immediately following sex and is not currently recommended by the CDC.2
Event-driven PrEP is recommended as an alternative schedule by the WHO for MSM who
find less than daily dosing more convenient, have sex less than twice per week on average, and can
postpone sex for two hours after initiating event-driven PrEP.74 Event-driven PrEP is administered
with a loading dose (two pills) 2 to 24 hours before sex, another dose (one pill) 24 hours after the
first dose, and a final dose (one pill) 48 hours after the first dose (hence the description, “2-1-1
PrEP”).74 If event-driven PrEP users continue to have sex after the initial loading dose, they should
continue to take one pill daily as long as sex continues and for two days after the last sexual
encounter.74 Event-driven PrEP is not recommended for women, transgender women on estrogen,
transgender men having vaginal sex, men who have sex with women, or people with chronic
hepatitis B infection.74 There is limited data on event-driven PrEP efficacy in non-MSM
populations with data suggesting tenofovir (TDF) may be less concentrated in the female genital
tract and less effective when administered with estrogen.74 A study of TDF/FTC drug levels in
transgender women on feminizing hormones found that TDF/FTC did not affect hormone levels,
but hormones decreased tenofovir plasma levels by 13% which does not reduce daily PrEP efficacy
but may reduce efficacy of event-driven PrEP.74
Tenofovir/emtricitabine is generally well-tolerated.2 Nausea is the most common sideeffect, present in less than 10% of users, and is often self-limiting within the first month of use.2
Adverse reactions to tenofovir/emtricitabine can include decreased bone mineral density, renal
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insufficiency, hepatitis B flare, and HIV viral resistance.2 Older adults and those with preexisting
renal disease are more at-risk for tenofovir/emtricitabine-associated renal impairment.58
tenofovir/emtricitabine is active against hepatitis B and irregular dosing or abrupt cessation can
increases risk for hepatitis B flare and subsequent liver impairment in those with chronic hepatitis
B infection.2 Hepatitis B is a vaccine-preventable illness transmitted through sex or blood contact
and has shared risk factors with HIV including injection drug use and multiple sex partners.75
Most cases of HIV viral resistance among PrEP users have been attributed to inappropriate
initiation of PrEP in individuals living with HIV who should have initiated HIV treatment instead
because tenofovir/emtricitabine alone is inadequate for HIV treatment.2 Observed HIV mutations
among PrEP users have included K65R and M184V conferring resistance to nucleoside reverse
transcriptase inhibitors tenofovir and emtricitabine respectively.2 Those who acquired HIV after
PrEP initiation were less likely to develop HIV viral resistance but rare transmission of
tenofovir/emtricitabine-resistant virus has been reported.2,76 Overall risk of HIV resistance among
PrEP users remains low when PrEP is used as directed.2
Long-Acting PrEP (LA PrEP) is an emerging PrEP delivery system currently in Phase III
clinical trials administered via injection every two to three months with two drugs, cabotegravir (an
integrase inhibitor) and rilpivirine (a non-nucleoside reverse transcriptase inhibitor).16,72 In clinical
trials, LA PrEP has been generally well tolerated with the most common side-effect of pain and
redness at the injection site.16 LA PrEP has the potential to improve PrEP adherence by reducing
daily pill burden although individuals must still adhere to injection dose schedules.16,72 LA PrEP
has a long pharmacologic tail and will likely require oral PrEP co-administration to avoid
subtherapeutic drug levels upon initiation and discontinuation.72 LA cabotegravir has been detected
one year after discontinuation in 14% of users.77
Subtherapeutic drug levels can increase the risk of HIV viral resistance if HIV is acquired
during this time which is concerning among those with poor adherence or those with acute HIV
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infection who were improperly initiated on PrEP.16,72,77 Mutations conferring resistance to
nucleoside and non-nucleoside reverse transcriptase inhibitors have been appreciated in PrEP users
in the setting of subtherapeutic drug levels.2,16 Mutations conferring significant resistance to all
integrase inhibitors have been appreciated among macaque studies assessing viral resistance
mutations in the setting of sub-therapeutic LA cabotegravir levels.77 Resistance to integrase
inhibitors and nucleoside reverse transcriptase inhibitors is concerning because these are currently
recommended as initial HIV treatment for most people in the US.78 Providers of LA PrEP may also
need to increase clinical capacity if LA PrEP injections are to be administered in a clinical
setting.72 Additional emerging PrEP delivery systems include injections with better tolerability,
implants, and new classes of medications.72
Psychosocial Benefits of PrEP
PrEP significantly reduces the risk of HIV acquisition, provides an opportunity to engage
at-risk populations in STI screening, and can have psychological and emotional benefits for PrEP
users.9,10,21,79 In qualitative studies, PrEP users and PLWH have reported feeling empowered with
reduced fear of HIV transmission and subsequent increased feelings of intimacy and pleasure
surrounding sex.9,79 PrEP user empowerment can be driven by control over their sexual health
reducing the need to rely on others to use condoms, adhere to ART, or disclose their HIV status.9,79
PrEP can also reduce HIV-related stigma as PrEP user social networks may be more inclusive of
PLWH where serosorting, exclusion of PLWH from social networks due to HIV status, has
occurred.9 PrEP users have reported increased inclusion of PLWH in relationships, knowledge of
HIV, and reduced anxiety, fear, or shame related to unknown HIV status.9,63
PrEP Uptake
In 2015, 1.2 million adults in the US were estimated to be eligible for PrEP of which the
primary HIV risk factors were MSM (71.1%) and injection drug use (22.5%).80 PrEP-eligibility has
varied by location and race with Blacks in the South in highest need.80 US PrEP uptake has
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increased since 2013.9 However, PrEP uptake in the US has been considered slow by public health
practitioners with disparities in racial and geographic access due to a combination of real and
perceived provider and client barriers including awareness, cost, stigma, and medical system
mistrust.17,81–85
A PrEP-to-need ratio (PnR) analysis of a national US prescription database using fourth
quarter 2017 data found variation in PrEP use with 30% of PrEP users in the South (PnR 1.0), 30%
in the Northeast (PnR 3.3), 23% in the West (PnR 2.1), and 17% in the Midwest (PnR 2.4).15 Low
PnR was found in states with lower rates of health insurance coverage, higher rates of poverty, and
larger population of Black residents which highlights disparities among those most at-risk for HIV
and those most likely to use PrEP.15 A county-level assessment of US PrEP providers relative to
MSM PrEP-eligible populations in 2017 found PrEP-deserts (areas without PrEP providers within
a 30-minute drive) were present among all US regions with worse disparities outside of urban
centers and in the South (17.1% compared to 5.4% in the Northeast).83 Rural areas of the West,
Midwest, and states of Georgia and Texas were more likely to have significant PrEP-deserts with
no PrEP providers within a 90-minute drive.83
Systematic barriers to PrEP uptake have included ineffective community engagement, lack
of clinical capacity, and cost.81 Inadequate identification and referral of PrEP-eligible clients can
limit PrEP access, legal restrictions can limit access to minors, and lack of funding or insurance
coverage has been the most commonly cited barrier to PrEP access by patients and providers.81
PrEP messaging has largely targeted cisgender MSM with less advertising toward injection drug
use, transgender, heterosexual, and minority populations that face unique stigma and disparities
accessing healthcare services.81 A cohort of 33 PrEP-eligible PWID in Massachusetts reported
multiple barriers to PrEP. Limited awareness of PrEP was the primary individual level barrier, and
additional barriers included drug use, homelessness, inconsistent engagement with the medical
system, and possible incarceration.84
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Barriers to formal PrEP access have prompted use of self-sourced PrEP through online
purchases or other informal channels.86 Informal PrEP users may forgo recommended screenings
(like HIV or renal function tests) and the quality and safety of informal PrEP sources is unknown.86
A qualitative study with 20 informal PrEP using MSM in the United Kingdom in 2017 found that
most users self-sourced PrEP through online purchase and one participant sourced PrEP from the
ART his partner used as HIV treatment.86 Many users verbalized concern about the legitimacy of
products purchased online but chose online purchase after seeing online PrEP advertised in a
medical setting or after failing to obtain PrEP through formal sources because PrEP was only
available through clinical trials in the United Kingdom at that time.86 Informal PrEP users reported
administering both daily and event-driven PrEP, and obtained information about PrEP dosing and
side-effects online, from medical providers and friends.86 The authors discussed that informal PrEP
users heavily relied on social networks for information and support, and users could benefit from
tailored interventions to promote adequate PrEP-related education, screening, and monitoring.86
Patient and Provider Barriers to PrEP Uptake
Patient barriers to PrEP uptake have included lack of knowledge of PrEP availability, low
awareness of HIV risk, and concerns about cost, side-effects, adhering to a daily pill schedule, and
stigma or mistrust of the medical system particularly among racial minorities, MSM, transgender
women, and PWID.9,81,82 PrEP is largely covered by insurance companies although many
individuals with and without insurance require financial assistance to obtain PrEP
(tenofovir/emtricitabine has been estimated to cost over $10,000 per year).82,87,88 Financial
assistance programs for copay and lab costs require knowledge of the medical system and clients
often need assistance navigating these bureaucratic processes.82 Furthermore, individuals with
government insurance (Medicare, Medicaid, and TRICARE) and minors under the age of 18 with
insurance coverage through a parent (but prefer not to use insurance due to confidentiality) are not
eligible for private pharmaceutical payment assistance programs.81
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Persistent stigma and racism surrounding HIV, homophobia, transphobia, perceived
promiscuity associated with PrEP use can prohibit eligible clients from accessing or using
PrEP.81,82,85 A qualitative study comparing perceptions of homophobia and racism as barriers to
PrEP among 35 gay, bisexual and MSM from sites in Massachusetts and Mississippi reported
Black MSM had higher mistrust of the medical system and reported experiences of anti-gay or
HIV-related stigma compared to non-Hispanic Whites.85 A qualitative study of 14 MSM PrEP
users in Seattle, Washington reported fear of PrEP-related stigma and concern about being labeled
as promiscuous or irresponsible for using PrEP by peers and medical providers.63 PrEP-related
stigma can lead to feelings of shame, guilt, and internal conflict regarding respondents’ sexual
health and PrEP use.63
Provider barriers to prescribing PrEP have included concerns about inadequate knowledge
or experience with PrEP; concerns about high cost or poor insurance reimbursement that may
burden the patient or practice; risk of toxicity or side-effects; patient adherence and HIV resistance;
risk compensation; prejudice and stigma toward those at-risk for HIV; and feeling that PrEP was
not within their domain.17,81 There has been a significant paradox between ideal PrEP providers and
those most likely to care for PrEP-eligible clients.81 HIV specialists (those most knowledgeable
about PrEP) are less likely to see HIV negative PrEP-eligible clients while primary care providers
(those most likely to see PrEP-eligible clients) are often less trained on providing PrEP.81
PrEP Adherence and Seasons of Risk
High attrition to PrEP has been appreciated.18,89,90 A review of 7,148 PrEP users from a
national US pharmacy database from 2015 to 2017 revealed only two of five clients persisted with
PrEP for two years.18 Fifty-six percent of the cohort continued PrEP through the first year of use,
and 63% of those who continued PrEP through year one continued PrEP through year two.18
Factors associated with increased adherence were male, over age 24, copay less than $20, and
having commercial insurance.18 Women and youth age 18 to 24 were less likely to have persistent
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PrEP use after one year.18 The Adolescent Trials Network 110/113 study compared self-adherence
to PrEP with tracked pill bottle systems and drug concentrations via hair sample and dried blood
spots among 243 participants age 15 to 24 years.89 By week 48, half of the adolescent participants
took fewer than two PrEP doses per week per hair or blood measures, 20% took daily PrEP as
directed, and adherence self-report was generally overestimated.89
A retrospective review of 107 PrEP users at five outpatient clinics associated with an urban
academic medical center in New York from 2011 to 2015 found that 58% of PrEP users
discontinued PrEP within the first six months.91 The primary reason for discontinuing PrEP was a
change in perceived HIV risk due to ending a relationship with a partner living with HIV.91 Factors
associated with PrEP discontinuation were heterosexual orientation and initiation of PrEP due to
having a sex partner living with HIV.91 Age, gender, race, and insurance status were not associated
with PrEP discontinuation.91
A longitudinal cohort qualitative survey of 36 former PrEP users who identified as gay or
bisexual men found that primary reasons for discontinuing PrEP included cost, insurance
discrepancy, side-effect, or difficulty taking a pill daily.90 Many participants also reported
fluctuations in behavior resulting in lower perceived HIV risk.90 Behavior changes that lead to a
perceived lower HIV risk included decreased number of partners, engagement in drug or alcohol
treatment, condom use, and TasP among monogamous serodiscordant partnerships.90 Former PrEP
users who discontinued PrEP due to perceived lower HIV risk also reported intent to restart PrEP if
risky behaviors were resumed.90
Periodic or cyclical fluctuation in risk behavior has been termed ‘Seasons of Risk’ and has
impacted willingness to use PrEP among multiple eligible populations.92 A qualitative study of 38
MSM and male sex workers assessing seasonal risk in Providence, Rhode Island in 2012 found
increased risk and willingness to use PrEP during periods of vacation or holiday, summer social
activities, and increased drug and alcohol use.92 The majority of male sex workers reported
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substance use with increased perceived risky behavior during periods of drug use or relapse,
poverty, and housing insecurity.92 Male sex workers reported increased PrEP interest but decreased
PrEP access during periods of increased risk due to poverty, homelessness, lack of transportation,
feelings of hopelessness or shame, and not prioritizing health.92
An internet survey of 7,305 MSM in the US in 2013 found that sexual risk behavior was
generally seasonal with increased risk during periods of vacation and travel.93 Daily PrEP
administration was a reported barrier among 92.6% of survey respondents, most respondents
preferred less than daily dosing of PrEP, and 74.3% reported willingness to use daily PrEP if they
perceived it beneficial for short periods.93 The authors discussed that administering PrEP daily for
short intervals during periods of increased risk (like vacations) may be more attractive to PrEPeligible individuals than long-term daily PrEP, and more research was needed to determine if daily,
short-term daily, or event-driven (2-1-1) PrEP would be most beneficial to study participants.93
Data on PrEP among women in the US is lacking, and reasons for discontinuing PrEP
among women may differ from men.94 A qualitative study of 60 women in Kenya and South Africa
found that 47% of survey respondents would likely stop PrEP in the future.94 Those who expected
to discontinue PrEP reported reasons of lower perceived HIV risk including no longer being
sexually active or perceiving their partner to be of low risk.94 Some women reported they would be
likely to discontinue PrEP due to social pressure or stigma, in perinatal periods fearing PrEP may
harm fetal development, or due to older age.94 Four women in the study reported intent to stop
PrEP during periods of life stress, and six reported intent to stop PrEP if they were traveling
because they did not want to travel with medication or perceived they would not have time to
administer the medication while traveling.94 The authors discussed that PrEP providers should
recognize social and cultural norms, consider providing PrEP education to women and their male
partners, and educate women on safety and efficacy of PrEP surrounding pregnancy.94
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Interventions to increase PrEP adherence should be tailored to meet individual adherence
barriers.95 Individuals can have difficulty obtaining refills from pharmacies, remembering to take a
daily pill, and have attitudes or perceptions that reduce uptake and adherence to PrEP.95 LA PrEP is
expected to improve adherence among users who have difficulty adhering to daily pill schedules,
and event-driven PrEP may improve adherence among eligible MSM who prefer less than daily
dosing.16,74 PrEP delivery systems can also model HRSA Ryan White HIV/AIDS Program services
to reduce disparities in access to care and improve ART adherence among at-risk populations as
those at-risk for HIV generally face the same barriers to care and adherence as PLWH.96 Ryan
White HIV/AIDS Program services use a multidisciplinary approach that often includes HIV
specialists, social workers, and mental health professionals.96 Ryan White HIV/AIDS Program sites
that performed a comprehensive needs assessment and integrated provision of ART with primary
care have generally demonstrated superior outcomes.96 Likewise, PrEP providers that perform a
comprehensive needs assessment and integrate provision of PrEP with primary care may also
increase access and adherence.96
Cost and Resource Allocation
Assessing cost-benefit of HIV prevention is complex and largely dependent on local
factors including HIV prevalence, characteristics of at-risk populations, healthcare infrastructure,
cost, and availability of resources.6,13,14,97 HIV prevention interventions are often divided into
categories along a prevention cascade including behavior risk reduction (condoms), biomedical
prevention (PrEP), HIV testing, linkage to care, HIV treatment and retention in care (TasP).6 In the
US, the cost of PrEP and HIV prevention is variable and dependent on factors including generic
availability, insurance coverage, laboratory and provider fees, 340B drug-pricing, and eligibility for
pharmaceutical payment assistance programs.13,87,88,98 ART medications are the largest cost item to
PrEP delivery as payers are charged over $1,000 for a 30-day supply of tenofovir/emtricitabine in
the US.87 ART cost is often shared by insurance payers and pharmaceutical payment assistance
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programs.88,99 Clinical care (laboratory, testing, and provider fees) are variable depending on the
type of test ordered and are often funded by insurance payers or state and local funding among
uninsured populations.87,99,100
A cost analysis of unmet need (no funding coverage or inadequate funding coverage) to
fund PrEP medication, clinical visits, and laboratory costs in the US in 2015 found that the percent
of individuals with health insurance coverage to fund PrEP varied by transmission category (PrEPeligible MSM were more likely to have private insurance than women or PWID).100 The authors
estimated the national cost of covering PrEP for all eligible individuals in 2015 was about $208
million per year ($119 million to cover the cost of those in need of assistance for clinical care only,
and $89 million to cover the cost of those in need of assistance for clinical care and ART).100 The
authors discussed that providing PrEP for all eligible people is less than the allocated funds
available for HIV care and treatment (19.7 billion in fiscal year 2016), PrEP uptake has been
generally slow, and not all eligible people have attempted to access PrEP.100
In the US, condom use as HIV prevention has been estimated to cost less than $4 annually
per person while PrEP can cost over $10,000 annually per person but is more effective than
condoms when used as directed for HIV prevention.87,97,98 PrEP has more cost-effectiveness when
delivery is targeted toward those at highest risk for HIV, like MSM, although allocating resources
to PrEP may divert resources from less expensive prevention methods or HIV treatment and has
not been supported as the most cost-effective HIV prevention intervention.13,98 Conversely,
interventions supporting HIV treatment, adherence, and retention in care (TasP) have been largely
supported as a cost-effective strategy to maximize health benefits among varying populations,
including heterosexual and PWID, in the US and globally.6,14,97,98 A review of HIV program cost
analysis in 23 countries found that increasing funds to treat HIV would reduce new HIV infections
and HIV-related death and the degree of impact varied by resource availability.14 The analysis
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supported targeting populations with the highest HIV incidence and optimizing ART availability
for PLWH before increasing capacity for HIV testing and counselling.14
Resource allocation for STI and HIV prevention in LHDs is critical for population STI
prevention.101 LHDs are a safety-net for low income, uninsured and underinsured populations, and
are ideal providers of PrEP as they are engaged with populations at-risk for HIV.101 Data has
supported an inverse relationship between bacterial STI incidence and LHD STI funding with
higher rates of gonorrhea and syphilis in periods of lower funding.101,102 Despite public need,
federal funding for public health STI prevention has declined since 2002 and future budget
restrictions are expected.101,102 A 2013 and 2014 survey of 148 US LHDs recruited from the
National Association of County and City Health Officials’ (NACCHO) 2010 National Profile of
Local Health Departments survey found that 61.5% experienced STI budget cuts in the previous
fiscal year; about 40% reduced STI clinic hours of operation and STI screening due to budget cuts
and 6.8% closed STI clinics due to budget cuts.101 Reduced funding for LHD STI programs can
negatively impact populations most vulnerable to HIV and STIs.101,102
PrEP in Local Health Departments
US public health agencies are critical providers of HIV prevention services, and LHDs are
in an ideal position to support PrEP delivery and leverage data.1,6,101,103 Most available literature on
PrEP delivery has been collected in clinical trial or academic settings, and little data on PrEP
delivery in local health departments exist. Available data on PrEP delivery in LHDs have
predominantly assessed LHD engagement or willingness to provide PrEP services. Despite the
critical role of LHDs in STI and HIV prevention in the US, data regarding population outcomes of
PrEP provision by LHDs is a current gap in the literature, and no literature on STI incidence among
LHD PrEP users or PrEP provision by LHDs in the US state of Georgia could be identified.
A 2015 US survey of 284 LHDs on PrEP engagement found 29% of respondents were
engaged in PrEP services through activities including linkage to PrEP care (74%), PrEP education
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to community members (51%), or participation in state or local PrEP workgroups (32%).1 LHDs
engaged in PrEP services were most often located in the West (47%) and served large jurisdictions
(68%).1 LHDs engaged in PrEP services were also more likely to provide HIV testing (98%), HIV
linkage to care (83%), or operate STI clinics (81%) than those not engaged in PrEP services.1 Only
9% of survey respondents reported actively providing PrEP and barriers to PrEP provision at the
LHD level included concerns about clinical capacity (61%), cost to clients (53%), and lack of
knowledge among staff (47%).1 A 2016 survey of 56 LHDs in North Carolina regarding PrEP
provision found that two LHDs actively provided PrEP and seven referred clients to PrEP services.
Primary reasons for LHDs not engaging in PrEP were concerns about cost, lack of PrEP
prescribing protocol, and belief that PrEP provision was more appropriate for non-LHD clinics.104
The NGHD, a LHD in north Georgia, aims to optimize local population HIV and STI
health outcomes in coordination with national and state prevention goals. The Georgia Integrated
HIV Prevention and Care Plan for 2017-2021 goals include preventing new infections, improving
access to care and health outcomes, and reducing HIV-related health disparities.105 To achieve
these goals, the NGHD started providing PrEP services in July 2019 in addition to previously
existing STI and HIV prevention and treatment services. PrEP services provide the NGHD an
opportunity to screen, refer, and vaccinate a population that may otherwise be unengaged in care or
forgo services. PrEP users at NGHD LHD study sites are routinely screened for HIV, STIs, and
hepatitis C; mental health conditions like depression; substance use including tobacco, alcohol, and
illicit drug use; and vaccination status. Treatment and referrals are provided as needed.
PrEP Program Performance Evaluation
The WHO has described PrEP delivery as a cascade of services where individuals at-risk of
HIV are identified and linked to PrEP care, screened for interest and eligibility, provided PrEP,
retained in care with optimal adherence, and discontinue PrEP as indicated.106 Routine program
monitoring is essential to assess PrEP uptake, effectiveness, and to predict demand.106 The WHO

47
has recommended that program measures assess each step in the PrEP delivery cascade to
determine if the program is reaching the target population with safe, effective, and sustained PrEP
care.106 The WHO has suggested PrEP program measures include PrEP uptake, retention in PrEP
care for more than three consecutive months, PrEP toxicity, and seroconversion (number of PrEP
users who are diagnosed with HIV).106 The CDC has suggested PrEP program quality measures
include presence of baseline HIV screening before initiating PrEP, interval HIV screening, PrEP
medication adherence, seroconversion, and seroconversion with ART-resistant HIV.107 No national
US PrEP program comparison benchmarks could be identified.
A PrEP program evaluation in New York assessing 171 PrEP users from five clinics
throughout the state from 2014 to 2015 found that the primary demographics of PrEP users were
male (93.6%), white (60%), age 25-34 (46%), with predominant risk factor of anal sex (55.2%),
and most had private insurance (66.7%).108 Twenty-four percent of the cohort discontinued PrEP
within the 12-month study period and the majority discontinued PrEP within the first six months of
PrEP use.108 The primary reason for PrEP discontinuation was a change in perceived HIV risk.108
One client seroconverted with HIV between PrEP initiation and one-month follow-up, 17 PrEP
users were found to have a bacterial STI on PrEP intake, and 9 were found to have a bacterial STI
on 6-month screening.108 Eighty-three PrEP users responded to a survey on their experience with
PrEP and generally reported being satisfied with PrEP with 94% of respondents reporting they
would recommend PrEP to a friend and 82% reporting less worry of HIV.108 Thirty-three percent
reported having insurance issues related to PrEP, and a high deductible or copay for laboratory or
provider fees was the primary insurance-related issue.108 Staff reported that developing
infrastructure to support PrEP delivery (PrEP-related clinical training and increased administrative
support) was essential to successfully initiate a PrEP program.108 No program evaluation of PrEP
services, retention in care or STI incidence among PrEP users in a Southeast US LHD setting could
be identified despite the key role of LHDs in community STI prevention. This practice-based study
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served to provide NGHD leadership with data to evaluate PrEP program delivery and guide
decision-making in absence of available LHD PrEP service data.
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CHAPTER 3
METHODS
The goal of this study was to perform an evaluation of LHD PrEP services in the North
Georgia Health District (NGHD), a local health department that includes six counties in north
Georgia, between July 2019 and June 2020 (the first year PrEP services were provided), quantify
the impact of COVID-19 on NGHD STI testing services, and determine how the Thinking
Ethically framework can be effectively applied to PrEP-related public health practice. The study
was performed through a secondary analysis of longitudinal data obtained through a retrospective
review of NGHD PrEP client medical records from July 1, 2019 to June 30, 2020; aggregated
NGHD STI testing from July 1, 2017 to June 30, 2020; and an analysis of literature cited in this
study. The study was approved by the Georgia Southern University Institutional Review Board
(Appendix A).
Data obtained from this study were intended to be applied by NGHD leadership to guide
future PrEP service delivery, determine the rate of bacterial STI diagnosis among PrEP users, and
determine what additional services were provided to PrEP users beyond STI prevention. Outcomes
included PrEP user demographics; length of time users were enrolled in the program; diagnosis of
HIV, gonorrhea, chlamydia, syphilis among PrEP users; type of additional services provided to
PrEP users; sum of NGHD STI tests performed; and ethical considerations to PrEP services
identified via literature review. It was assumed that PrEP services provide an opportunity to engage
a population that may otherwise forgo health services and routine STI screening. Individuals with
asymptomatic STIs may forgo routine STI screening with subsequent delays in STI diagnosis and
treatment. Routine STI screening among PrEP users benefits timely STI treatment and prevention.
The study period included the onset of the 2020 COVID-19 pandemic, and it was assumed
that the COVID-19 pandemic impacted NGHD STI and PrEP service delivery. The number of total
STI tests (HIV, gonorrhea, chlamydia, and syphilis) provided by the NGHD between July 1, 2017
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and June 30, 2020 were assessed in attempt to quantify the impact of the COVID-19 pandemic on
NGHD STI services. Total STI tests provided during this period provided NGHD leadership with
baseline data to determine when STI services return to pre-pandemic quantity. NGHD STI testing
services were assessed because HIV prevention and PrEP should be considered in the context of a
broad STI prevention strategy.10,11 The study served to answer the following research questions:
1. How can the Thinking Ethically framework be used to inform public health practitioners on
PrEP-related decision-making?
2. Did NGHD PrEP services reach those most at-risk for HIV in the district?
3. How long did PrEP users stay in the program?
4. What additional services were provided to PrEP users beyond STI prevention?
5. How many asymptomatic bacterial STIs were diagnosed among PrEP users?
6. How much did NGHD STI testing change in the period associated with the onset of the
COVID-19 pandemic?
The research questions were developed with consideration to NGHD STI screening
priorities along with CDC and WHO recommended PrEP practice quality indicators which include
appropriate screening, retention in care, and the number of patients with confirmed HIV diagnosis
while prescribed PrEP medication.106,107 The questions were framed with regard to the Thinking
Ethically framework which incorporates multiple ethical principles and uses a stepwise approach to
ethical decision-making.5 All Thinking Ethically principles (justice, utility, rights, common good,
and virtue) were analyzed in research question 1, and the principles of justice (the fair distribution
of resources) and utility (acting to produce the greatest net benefit) were used to frame research
questions 2 – 6.5 Ethical considerations surrounding NGHD PrEP services have included reaching
the target population as those at-risk for HIV are often vulnerable or hard to reach and may require
allocation of additional resources,3 and the potential impact of PrEP services on the broader STI
landscape as PrEP use has been associated with increased bacterial STI incidence and those at-risk
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for HIV are often at-risk for other STIs.10,11 PrEP user demographics and length of time enrolled in
the PrEP program were assessed to determine if NGHD PrEP services equitably reach those at-risk
for HIV in the district (justice approach). Additional non-HIV prevention services provided to
PrEP users (like vaccination or referrals) and asymptomatic bacterial STI diagnosis among PrEP
users were assessed to weigh the net benefits of NGHD PrEP services and potential impact of PrEP
provision on the STI landscape (utility approach).
It was assumed that the medical record was an accurate reflection of the medical encounter
and the Thinking Ethically framework would benefit PrEP-related public health decision-making in
practice. It was expected that the NGHD had between 50 and 100 PrEP users within the study
period and minority of PrEP users were prescribed PrEP with on-demand (2-1-1) administration. It
was expected that the NGHD PrEP user population was largely homogenous in race (White),
ethnicity (non-Hispanic), gender (male), and primary HIV risk factor (MSM), and differed in age.
It was estimated that length of time in PrEP care would mirror the experience of other PrEP clinics
with 20-50% of PrEP users discontinuing PrEP within the first six months. Providing PrEP services
was expected to benefit NGHD ability to identify asymptomatic bacterial STIs through routine
screening. Duplicate bacterial STI diagnoses were expected in some cases and were not considered
an error in data collection (for example, clients diagnosed with pharyngeal and urethral gonorrhea
on the same screening encounter). It was expected that PrEP users were provided with additional
services including routine vaccination, referrals (primary care, mental health care, social services),
and tobacco cessation counseling as indicated. It was expected that the largest disruption in NGHD
STI testing services associated with the onset of the COVID-19 pandemic occurred between April
and June 2020.
The NGHD provides PrEP to eligible clients using the Georgia Department of Public
Health (DPH) Registered Nurse Protocol and CDC guidelines. NGHD clients are eligible for PrEP
if they meet DPH and CDC criteria which include a primary HIV risk factor of MSM,
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heterosexually active men and women, and PWID with additional risk factors including multiple
partners, recent bacterial STI, inconsistent condom use, or partner living with HIV.2 Clients must
have documented negative HIV test and no sign of acute HIV, no medical contraindication to
tenofovir/emtricitabine, and be willing to return for follow-up one month after starting PrEP and
three months thereafter. Screening for syphilis, gonorrhea, and chlamydia via 3-point testing
(pharynx, urethral or vaginal, and rectal) is performed on the initial PrEP encounter and every six
months (more frequently as needed). The NGHD postponed in-person PrEP visits in the second
quarter of 2020 due to the COVID-19 pandemic during which time PrEP users were provided with
prescription refills if they were able to be contacted by phone, had no symptoms of acute HIV,
verbalized adherence to PrEP and willingness to continue therapy.
Sample and Population
The cohort was selected via convenience sampling. Medical records of all PrEP users in
the NGHD from July 2019 to June 2020 (the first year that PrEP services were provided) were
reviewed. Sixty-three clients obtained PrEP from the NGHD during the study period and were
included in the study. During the study period, the NGHD provided PrEP only to those over 18
years of age, so only data from those of 18 years or older were included in the study. NGHD PrEP
users who tested positive for HIV were to be included in the cohort until date of HIV diagnosis, but
no NGHD PrEP users were diagnosed with HIV during the study period. The study also examined
the total number of STI tests performed by the NGHD from July 2017 through June 2020 to
quantify the degree of service delivery change associated with the onset of the COVID-19
pandemic. This data included all HIV, gonorrhea, chlamydia, and syphilis tests performed at
NGHD clinic sites. Tests of HIV, gonorrhea, chlamydia, and syphilis not performed at NGHD
clinic sites were excluded.
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Data Collection
Data to inform analysis of the Thinking Ethically framework used literature cited in this
study (research question 1). Client data was obtained via a retrospective chart review of NGHD
electronic medical record data from all NGHD PrEP clinic sites (research questions 2 – 6). Data
obtained included PrEP user age, race/ethnicity, sex/gender, HIV risk factor, bacterial STI
diagnosis, length of time on PrEP, and NGHD clinic site. Data on presence of STI symptoms at the
time of bacterial STI diagnosis was obtained to determine the rate of asymptomatic STIs diagnosed
through routine program STI screening. Data on additional services provided (like vaccination and
referrals) were obtained to assess benefits of PrEP provision beyond STI prevention. To protect
privacy, data was recorded in deidentified form, each NGHD clinic site was assigned a confidential
name (Clinic A, Clinic B, Clinic C), and clinics with fewer than 10 PrEP users were reported in
aggregate form instead of confidential clinic name to protect client confidentiality as some NGHD
sites had low PrEP program census.
NGHD district-level HIV, gonorrhea, chlamydia, and syphilis data from July 2017 to June
2020 were assessed using an electronic medical record STI report utilized by the district to
routinely assess STI incidence (research question 6). This report had no patient identifiers and was
captured in Excel software. Data was captured using a secured on-site computer on an Excel file
without any personal identifiers and stored on the researcher’s password-protected computer and
NGHD internal password-protected virtual drive.
Data Analysis
Research Question 1
Analysis and synthesis of the Thinking Ethically framework (research question 1) was
performed using literature cited in this study and study outcomes of research questions 2 – 6.
Outcomes included pairing each Thinking Ethically principle (utilitarian, justice, rights, common
good, and virtue) with a PrEP-related ethical consideration. An analysis was performed to

54
determine how the Thinking Ethically framework benefits PrEP-related public health practice and
decision-making.
Research Questions 2 – 5
Chart review data from July 1, 2019 to June 30, 2020 was analyzed using Excel and SPSS
version 27 software to answer research questions 2-5. NGHD PrEP user demographic variables
(clinic site, age, race/ethnicity, sex/gender, and HIV risk factor), presence of any additional
services provided to PrEP users, months in program, and asymptomatic STI diagnosis among PrEP
users were assessed. To determine how long NGHD PrEP users stay in the program, client length
of time using PrEP was assessed in months (four weeks) from the initial encounter date to the end
of the study period or to the date of last documented contact with the client, whichever came first.
Discontinuation dates that fell between two months were rounded to the nearest month, and data of
one client who discontinued and restarted PrEP within the study period reflected the sum months of
program participation.
Descriptive statistics including means, standard deviation, and frequencies were used to
answer research questions 2 – 5. Negative binomial and multiple logistic regression models were
performed to further assess research question 3. Regression analyses included 62 of the 63 PrEP
users in the study. Cohort demographic variables with low events per variable were transgender
(n=1), IV drug user HIV risk (n=1), and clients prescribed on-demand (2-1-1) PrEP (n=1). The one
transgender female was coded as female, the one IV drug user was excluded, and the one ondemand PrEP user was coded in the same way as daily PrEP users to reduce the risk of type 1 error
due to overfit of cohort data (Table 3.1). A forced entry approach including all independent
variables on the first step was used because previous literature suggested factors of age, HIV risk,
and race/ethnicity have been associated with PrEP use.18,85,89,91

55
Table 3. 1. Regression modeling variables and type
Dependent variables
Independent variables
(PrEP user
demographic variables)

Study Variable
Months in Program
Months in Program of 4 or More (yes/no)
Clinic Site:
Clinic A
Clinic B
Clinics C/D/E
Sex/Gender:
Male
Female
Race/Ethnicity:
Black non-Hispanic
White Hispanic
White non-Hispanic
Age
Primary HIV Risk Factor:
MSM
Heterosexual risk

Type
Continuous
Categorical
Categorical

Categorical

Categorical

Continuous
Categorical

Negative binomial regression. Negative binomial was performed to assess for association
between PrEP user demographics factors on probability of number of months in the PrEP program
(research question 3). The negative binomial regression model is a linear Poisson distribution with
the addition of a 𝜆 parameter to consider data variance in the equation. This improves the model fit
for data that is over-dispersed (variance greater than the mean) compared to a Poisson distribution
that assumes variance equals the mean. The negative binomial 𝜆 parameter follows a gamma
distribution (a continuous probability function that assesses the variance and mean to determine the
average waiting time for skewed events with a natural minimum of 0). Test assumptions were
presence of a continuous dependent variable, observations that are independent of each other, and
independent variables that have a multiplicative effect on the event. The following regression
function was used to predict the probability of months in program:

𝑃(𝑦𝑖 = 𝑛|𝑥𝑖 ) =

𝑦𝑖
𝑚𝑖
𝛤(𝑚𝑖 + 𝑦𝑖 )
𝑚𝑖
𝜆𝑖
(
) (
) ;𝑛 ≥ 0
𝛤(𝑚𝑖 )𝛤(𝑦𝑖 ) 𝜆𝑖 + 𝑚𝑖
𝜆𝑖 + 𝑚𝑖
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where 𝑃(𝑦𝑖 = 𝑛|𝑥𝑖 ) is the probability of the dependent variable occurrence, 𝛤 is the gamma
distribution, 𝑦𝑖 is the dependent variable, 𝑛|𝑥𝑖 is the independent variable with a positive
continuous 𝑛, 𝜆𝑖 is an exponential equation:
exp(𝑥𝑖 𝛽)
where 𝑥𝑖 is the independent variable and 𝛽 is the beta coefficient (a standardized measure
indicating the degree change in the outcome variable for every 1-unit change in the independent
variable), and 𝑚𝑖 is an exponential equation:
exp[(2 − 𝑃)𝑥𝑖 𝛽 − ln(𝛿)]
where 𝑃 is a probability, and ln(𝛿) is the natural log of delta (a difference in measures).
The dependent variable was PrEP user months in program as a continuous numerical
measure. The independent variables were PrEP user demographic factors. Clinic site compared
enrollment at Clinic A or Clinic B to Clinics C/D/E. Sex/gender compared females to males. HIV
risk factor compared those of heterosexual risk to MSM. Race/ethnicity compared Black nonHispanic or White Hispanic PrEP users to White non-Hispanic PrEP users. Age in years at program
enrollment was a covariate. Independent variables were considered statistically significant if the
corresponding p-value was less than 0.05.
Multiple logistic regression. Multiple logistic regression was performed to assess for
association between PrEP user demographic factors on odds of retention in care of four or more
months (research question 3). Four or more months was selected in accordance with recommended
WHO program measures to assess retention in care by consecutive PrEP use greater than three
months.106 The multiple logistic regression model solves for the odds of an outcome occurring and
calculates the natural log of the odds ratio so that the relationship can be plotted linearly. Test
assumptions were presence of a binary dependent variable, observations that are independent of
each other, little to no multicollinearity among independent variables, and independent variables
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should have 10 or more events per variable. The following regression function was used to predict
the odds of retention in care of four or more months:

ln (

𝑝̂
) = 𝑏0 + 𝑏1 𝑋1 + 𝑏2 𝑋2 +. . . +𝑏𝑝 𝑋𝑝
(1 − 𝑝̂ )

𝑝̂

where ln ((1−𝑝̂)) is the expected log of the odds that the outcome is present, 𝑝̂ is the expected
probability the outcome is present, 𝑋1 through 𝑋𝑝 are independent variables, and 𝑏0 through 𝑏𝑝 are
regression coefficients of the line.
The dependent variable was PrEP user months in program coded as ‘yes’ if the PrEP user
months in the program were four or more and ‘no’ if PrEP user months were three or less. The
independent variables were PrEP user demographic factors. Clinic site compared enrollment at
Clinic A or Clinic B to Clinics C/D/E. Sex/gender compared females to males. HIV risk factor
compared those of heterosexual risk to MSM. Race/ethnicity compared Black non-Hispanic or
White Hispanic PrEP users to White non-Hispanic PrEP users. Age in years at program enrollment
was a covariate. Independent variables were considered statistically significant if the corresponding
p-value was less than 0.05.
Research Question 6
The total number of STI tests performed by the NGHD was calculated from July 2017
through June 2020 using Excel software to determine how much NGHD STI testing changed in the
period associated with the onset of the COVID-19 pandemic (research question 6). STI testing
totals from July 2018 through June 2020 were assessed quarterly and totals were compared using
descriptive statistics. STI testing totals from July 2017 to June 2018 were excluded due to missing
or inconsistent data and it was determined that two years of historic STI testing data (July 2018 to
June 2020) were sufficient to assess changes associated with the onset of the COVID-19 pandemic.
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CHAPTER 4
RESULTS
Thinking Ethically About PrEP
Question 1: How can the Thinking Ethically framework be used to inform public health
practitioners on PrEP-related decision-making?
Providers of PrEP, HIV and STI care must make complex ethical decisions on resource
distribution and clinical services that can have significant public health impact. The Thinking
Ethically framework is of practical use to inform public health practitioners on PrEP, HIV and STIrelated decision-making by leading the practitioner to think critically and consider multiple ethical
perspectives in a step-by-step manner. Use of multiple ethical perspectives is necessary to
adequately assess the multifaceted nature of PrEP as decision-makers must consider available data,
available resources, and possibly conflicting stakeholder perspectives when providing PrEP
services.3 The Thinking Ethically framework facilitates practitioners to select the best plan of
action by first collecting data on an ethical issue and then evaluating outcomes against each ethical
principle (utilitarian, rights, justice, common good, and virtue).5 The following section serves to
demonstrate how the Thinking Ethically framework can be used to inform public health
practitioners on PrEP-related decision-making. Each question posed in the Thinking Ethically
framework will be addressed to exemplify the stepwise decision-making process as it applies to
providing PrEP care at the Local Health Department (LHD) level.
Which option will produce the most good and do the least harm? (The utilitarian
approach)5 The best decision from the utilitarian approach is one that produces the most good and
least harm for those impacted by the decision (greatest net gains).5 LHDs are key providers of HIV
and STI prevention, clinical, and data management services in the community101,103 and are
therefore ideal providers of PrEP services. Areas of high HIV incidence (like the Southeast US)
can have the greatest benefit from PrEP provision.23 PrEP services benefit timely bacterial STI
diagnosis and treatment10 and serve as an opportunity to engage a population that may otherwise
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forgo medical care. In this study, 75% of the bacterial STIs identified among NGHD PrEP user
were asymptomatic. Providing PrEP care offered an opportunity to identify, treat, and prevent
further transmission of asymptomatic STIs as it was assumed that those with asymptomatic STIs
may have delayed STI screening if they had not been engaged in PrEP services. About half of
NGHD PrEP users were also provided with non-HIV-related services including vaccination,
tobacco cessation counseling, and referrals as indicated; it was assumed that PrEP users may not
have engaged the medical system to obtain these services in absence of PrEP care. PrEP users have
also reported psychosocial benefits of PrEP including feelings of empowerment and reduced fear of
HIV.9
Potential risks of PrEP have included adverse reactions from ART and HIV viral resistance
among PrEP users if seroconversion occurs in the setting of subtherapeutic drug levels.2 ART used
in oral PrEP has been generally well tolerated, and the risk of developing HIV viral resistance
among oral PrEP users has been low.2 The rate of HIV viral resistance among Long Acting PrEP
(LA PrEP) users in the community is not yet known as LA PrEP is being studied in ongoing
clinical trials at the time of this study, although data has supported a risk of HIV viral resistance
among macaque LA PrEP models that can have significant implications for HIV care.77 LHD PrEP
providers will need to determine if the risk of HIV resistance outweighs the right of PrEP users to
access LA PrEP once approved and available for use.
Which option best respects the rights of all who have a stake? (The rights approach)5 The
best decision from the rights approach is one that honors the moral rights of those affected.5 Moral
rights include dignity, autonomy, privacy, to be told the truth and not injured.5 Ethical rights
surrounding PrEP can include the right to access PrEP, right to safe and effective therapy, and right
to privacy. LHD provision of PrEP services can serve to improve an individual’s right to access
PrEP as LHDs often provide care to vulnerable populations at-risk for HIV.101 Oral PrEP has been
generally well tolerated and considered up to 99% effective as HIV prevention when used as
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directed.2 Long Acting PrEP (LA PrEP) has also demonstrated high effectiveness in HIV
prevention in clinical trials although the risk of LA PrEP on HIV viral resistance in the community
is not yet known.72 The right to privacy surrounding PrEP can be complex; regulation requiring
involvement of parents in PrEP care may be required for minors.81 PrEP users may also be subject
to disclosures from laboratories or health insurers. For example, the primary insurance holder (like
a parent, guardian, or spouse) may receive an itemized statement of service charges or payments
from the laboratory or insurer that could inadvertently disclose PrEP use among minors or adult
PrEP users who are not the primary insurance holder.
Which option treats people equally or proportionately? (The justice approach)5 The best
decision from the justice approach is one that treats everyone equally, or unequally with a
justifiable standard (for example, income that is stratified by skill).5 When providing PrEP, LHDs
must determine how to fairly appropriate resources to provide PrEP to multiple at-risk populations
in addition to other public health priorities, like the ongoing COVID-19 pandemic response. PrEPdeserts have been appreciated in rural areas with worse access in rural areas of the US South,83 and
a low PrEP-to-Need (PnR) ratio has been appreciated in states in the South and non-Medicaid
expansion states compared to other regions of the US.15 This indicates that PrEP is not currently
equally distributed among those at-risk in the US. LHDs often serve as a healthcare safety net and
LHDs in Southeast and rural areas could improve PrEP distribution inequality by providing PrEP
services.
The NDHD integrated PrEP with its preexisting STI screening and treatment program in
2019, and staff was allocated to perform administrative tasks associated with PrEP care (like
assisting clients with enrollment in pharmaceutical payment assistance programs). The majority of
NGHD PrEP users were MSM despite a known population of PWID30 indicating that the NGHD
did not successfully reach all groups at-risk for HIV in the service area. Additional resources would
need to be allocated to reach and retain the NGHD IV drug user population in PrEP care as PWID
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have reported additional barriers to PrEP uptake including poor awareness, drug use, and low
socioeconomic status.84
Which option best serves the community as a whole, not just some members? (The common
good Approach)5 The best decision from the common good approach is one that benefits
community welfare for everyone (including vulnerable populations).5 Services including public
education, police and fire response are often evaluated from the common good approach.5 Ethical
considerations to LHD PrEP assessed in the utilitarian approach are also generally applicable for
analysis under the common good approach. Providing PrEP services can reduce HIV transmission
risk,2 improve timely diagnosis and treatment of non-HIV STIs,10 and provide an opportunity to
vaccinate individuals who may have otherwise forgone services. These services are beneficial to
the community as reducing HIV and STI transmission among individuals reduces community level
incidence, and vaccinating individuals improves community-level immunity. There has been
debate on whether to allocate ART to PrEP or HIV treatment in resource limited settings where
access to ART for treatment may be impacted if resources were allocated to PrEP care.3 Literature
has supported prioritizing ART for HIV treatment (Treatment as Prevention) instead of PrEP in
resource limited settings.98 The NGHD had adequate resources to initiate PrEP services without
restricting HIV treatment services.
Which option leads me to act as the sort of person I want to be? (The virtue approach)5
The best decision from the virtue approach is one that enable decision-makers to act in accordance
with their highest character standard.5 Honesty, compassion, integrity, self-control, and prudence
are common virtues used to evaluate acting from one’s best self.5 PrEP-related virtues include
compassion, fairness, and overcoming stigma and discrimination that surrounds HIV, STI, and
PrEP services. PrEP users have reported reduced stigma, fear and discrimination against PLWH
because of PrEP.9 Conversely, PrEP-eligible individuals have reported a fear of being labeled
promiscuous or irresponsible as a barrier to PrEP use.63 Many at-risk groups (MSM, transgender
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individuals, minorities, PWID) have also reported fear of stigma or discrimination when engaging
the medical system.84,85 LHDs should work to provide outreach and PrEP care in a culturally
sensitive manner to overcome stigma-related barriers to PrEP, HIV and STI prevention.
North Georgia Health District PrEP Services
Question 2: Did NGHD PrEP services reach those most at-risk for HIV in the district?
There were 63 NGHD PrEP users in the study period. NGHD Clinic A served 35 clients,
Clinic B served 18 clients; Clinics C, D, and E (C/D/E) served a total of 10 clients. Most NGHD
PrEP users identified as male followed by female and transgender. Most PrEP users identified as
White non-Hispanic followed by Black non-Hispanic and White Hispanic. The primary HIV risk
factor among PrEP users was MSM followed by heterosexual contact and intravenous drug use.
PrEP users were widely distributed in age with a range of 18 to 69 years (Figure 4.1). Most PrEP
users were under age 35 with 39.7% between 18 to 24 years followed by 25 to 34 years, 35 to 44
years, and over 45 years (Table 4.1). The median age was 28 years and mean age was 30 years with
a standard deviation of 11.5.
Figure 4. 1. Age and PrEP user primary HIV risk factor
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Table 4. 1. Count of cohort demographic factors
Demographic factor
Clinic Site:
Clinic A
Clinic B
Clinics C/D/E
Sex/Gender:
Male
Female
Transgender
Race/Ethnicity:
Black non-Hispanic
White Hispanic
White non-Hispanic
Age in years
18-24
25 to 34
35 to 44
45 or older
Primary HIV Risk Factor:
MSM
Heterosexual risk
Injection drug use

n

(%)

35
18
10

(55.6)
(28.6)
(15.9)

47
15
1

(74.6)
(23.8)
(1.6)

16
9
38

(25.4)
(14.3)
(60.3)

25
21
9
8

(39.7)
(33.3)
(14.3)
(12.7)

39
23
1

(61.9)
(36.5)
(1.6)

Study sites were found to have differing client demographic factors (Table 4.2). PrEP users
at Clinic A were 62.9% male followed by female, 48.6% White non-Hispanic followed by Black
non-Hispanic and White Hispanic, and with primary HIV risk factor of heterosexual risk followed
by MSM and injection drug use. PrEP users at Clinic B were 88.9% male followed by female and
transgender, 72.2% White non-Hispanic followed by Black non-Hispanic and White Hispanic, and
with primary HIV risk factor of MSM followed by heterosexual risk. PrEP users at Clinics C/D/E
were 90% male followed by female, 80% White non-Hispanic followed by White Hispanic, and
with primary HIV risk factor of MSM followed by heterosexual risk.
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Table 4. 2. PrEP user demographics by clinic site
Demographic Factor

Clinic A

Clinic B

Clinics C/D/E

Sex/Gender:
Male
Female
Transgender Female

62.90%
37.10%
0%

n=22
n=13
n=0

88.90%
5.60%
5.60%

n=16
n=1
n=1

90%
10%
0%

n=9
n=1
n=0

Race/Ethnicity:
Black non-Hispanic
White non-Hispanic
White Hispanic

40%
48.60%
11.40%

n=14
n=17
n=4

11.10%
72.20%
16.60%

n=2
n=13
n=3

0%
80%
0%

n=0
n=8
n=2

Primary HIV Risk Factor:
MSM
Heterosexual
PWID

42.90%
54.30%
2.90%

n=15
n=19
n=1

83.30%
16.70%
0%

n=15
n=3
n=0

90%
10%
0%

n=9
n=1
n=0

Question 3: How long did PrEP users stay in the program?
The NGHD had 22 active PrEP clients at the end of the study period and 41 of 63 clients
(65%) discontinued PrEP use during the study period. Of the 41 clients that discontinued PrEP,
90.2% (n=37) were lost to follow-up with unknown or undocumented reason in the medical record,
4.9% (n=2) discontinued due to a change in HIV risk, 2.4% (n=1) moved out of the service area,
and 2.4% (n=1) discontinued due to medication side effect. The highest monthly NGHD PrEP
census was in January 2020 (n=36), and a drop in census associated with the time of the onset of
the COVID-19 pandemic was appreciated. NGHD PrEP census declined by 27.8% between
January and March 2020 (36 to 26 PrEP users) but remained largely consistent between April and
June 2020 with 23 PrEP users in April and 22 PrEP users in June (Figure 4.2).
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Figure 4. 2. Total NGHD PrEP users per month
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Study sites were also found to have differing census, mean, median, and mode monthly
retention during the study period (Table 4.3; Figure 4.3). Clinic A had 35 PrEP users with the
lowest mean monthly retention (1.8 months). Clinic B had 18 PrEP users with a mean monthly
retention of 6.9 months. Clinics C/D/E had 10 PrEP users with a mean monthly retention of 7.7
months. Clients with less than one month enrolled in the program were found to have attended an
intake PrEP appointment for a PrEP eligibility screen and pre-prescription laboratory testing but
either fell out of care before being prescribed PrEP therapy or did not attend the one-month followup appointment.
Table 4. 3. PrEP user months in program by clinic site
Clinic Site
Clinic A
Clinic B
Clinics C/D/E

Mean
1.8
6.9
7.7

Median
1
6
11

Mode
0
6
11

Range
0 to 11
1 to 12
0 to 12

Note: mean, median, mode and range of PrEP user months in program
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Figure 4. 3. PrEP user months in program by clinic site
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A negative binomial regression was performed to assess the effect of PrEP user
demographic variables on months enrolled in the PrEP program (Table 4.4). Test assumptions of
presence of a continuous dependent variable, observations that are independent of each other, and
independent variables that have a multiplicative effect on the event were met. The negative
binomial regression model was statistically significant with Omnibus test of model coefficients
𝑋 2 =24.606, p=.001 with a p-value <.05 indicating significance. Clinic A was the only PrEP user
demographic factor that was significantly associated with months in program. PrEP user months in
program were 76% lower in Clinic A compared to Clinics C/D/E with a 95%CI of 35.6% to 91%.

Table 4. 4. Negative binomial regression for PrEP user demographic factors on probability of months in the PrEP program
95% Wald CI
Demographic Factor
B
Std.Error
Lower
Upper
Wald
(Intercept)
2.151
.6651
.847
3.455
10.458
Clinic Site
Clinic A
-1.426
.5031
-2.412
-.440
8.029
Clinic B
-.120
.4328
-.969
.728
.078
Clinics C/D/E
0a
.
.
.
.
Sex/Gender
Female
.482
.5725
-.640
1.604
.709
Male
0a
.
.
.
.
Race/Ethnicity
Black non-Hispanic
.517
.3959
-.259
1.293
1.703
White Hispanic
-.036
.4332
-.885
.813
.007
White non-Hispanic
0a
.
.
.
.
HIV Risk Factor
Heterosexual
-.822
.5545
-1.909
.265
2.196
MSM
0a
.
.
.
.
Age in Years
-.003
.0152
-.033
.027
.031
Abbreviations: CI, confidence interval
Note: 𝑋 2 =24.606, p=.001 (Omnibus)
a. Category reference variable
Bold text indicates statistically significant demographic variables at p <0.05

95% CI for EXP(B)
Lower
Upper
2.333
31.647

df
1

Sig.
.001

Exp(B)
8.593

1
1
.

.005
.781
.

.240
.886
1

.090
.380
.

.644
2.070
.

1
.

.400
.

1.619
1

.527
.

4.974
.

1
1
.

.192
.933
.

1.677
.964
1

.772
.413
.

3.643
2.254
.

1
.
1

.138
.
.861

.440
1
.997

.148
.
.968

1.304
.
1.028
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A multiple logistic regression was performed to assess the effect of PrEP user demographic
factors on odds of retention in care of four or more months (Table 4.5). Test assumptions of a
binary dependent variable, observations that are independent of each other, and little to no
multicollinearity among independent variables were met. Test assumption that independent
variables should have 10 or more events per variable were met for all independent variables except
HIV risk factor of White Hispanic (n=9). The logistic regression model was statistically significant
with Omnibus test of model coefficients 𝑋 2 =36.296, p=.000 with a p-value <.05 indicating
significance. Hosmer and Lemeshow test 𝑋 2 =4.183, p=.840 with a p-value >.05 indicating good
model fit. The model explained 59.3% (Nagelkerkle 𝑅 2) of the variance in months in program of
four or more months and correctly classified 83.9% of cases compared to 54.8% of cases in the null
model. Clinic A was the only PrEP user demographic factor that was significantly associated with
retention in care of 4 or more months. PrEP users in Clinic A were .017 times less likely to stay in
the program 4 or more months than those in Clinics C/D/E with a 95%CI of .001 to .218 times.
Table 4. 5. Logistic regression for PrEP user demographic factors on odds of months in program of
four or more months
95% CI for EXP(B)
Demographic Factor
B
S.E.
Wald
df
Sig.
Exp(B)
Lower
Upper
Clinic Site
Clinics C/D/E
15.500
2
.000
Clinic A
-4.079
1.304
9.791
1
.002
.017
.001
.218
Clinic B
.057
1.078
.003
1
.958
1.058
.128
8.755
Age in Years
-.041
.034
1.464
1
.226
.960
.898
1.026
Sex/Gender
Female
1.262
1.622
.605
1
.437
3.533
.147
84.933
HIV Risk Factor
Heterosexual
-2.062
1.615
1.630
1
.202
.127
.005
3.014
Race/Ethnicity
White non-Hispanic
3.123
2
.210
Black non-Hispanic
1.416
1.024
1.911
1
.167
4.120
.554
30.667
White Hispanic
-1.071
1.144
.876
1
.349
.343
.036
3.228
Constant
3.339
1.731
3.722
1
.054
28.204
Abbreviations: CI, confidence interval
Note: 𝑋 2 =36.296, p=.000 (Omnibus); 𝑋 2 =4.183, p=.840 (Hosmer & Lemeshow); .593 (Nagelkerkle 𝑅2 )
Bold text indicates statistically significant demographic variables at p <0.05
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Question 4: What additional services were provided to PrEP users beyond STI prevention?
About half (50.8%, n=32) of NGHD PrEP users had documentation of additional services
beyond STI prevention provided during the PrEP encounter. Of the additional services provided, 17
PrEP users were provided vaccines, 11 PrEP users were provided referrals, 5 PrEP users were
provided alcohol reduction counseling, and 4 PrEP users were provided smoking cessation
counseling. Vaccines provided were hepatitis A, hepatitis B, influenza, tetanus-diphtheriapertussis, and human papillomavirus. Referrals provided were primarily to Federally Qualified
Health Centers for primary care, social services for food or housing assistance, mental health
providers, or other NGHD site for vaccination (Table 4.6).
Table 4. 6. Count of additional services provided
Service Provided
Vaccines
Hepatitis A
Hepatitis B
Influenza
Tdap
Human papillomavirus
Referrals
Primary care
Food or housing assistance
Mental health
Other NGHD site
Health Behavior Counseling
Alcohol reduction counseling
Smoking cessation counseling

n

(%)

9
2
5
4
6

(34.4)
(7.7)
(19.2)
(15.4)
(23.1)

6
2
2
2

(50)
(16.7)
(16.7)
(16.7)

5
4

(55.6)
(44.4)

Question 5: How many asymptomatic bacterial STIs were diagnosed among PrEP users?
Most PrEP users (81%, n=51) were not diagnosed with an STI (HIV, gonorrhea,
chlamydia, or syphilis) during the study period, and 19% (n=12) of PrEP users were diagnosed
with an STI during the study period. There were 16 STI cases of which 50% (n=8) were chlamydia,
31.3% (n=5) were gonorrhea, 18.8% (n=3) were syphilis, and none were HIV. The majority of STI
cases (75%, n=12) had no symptoms documented at time of STI screening as 62.5% (n=5) of
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chlamydia cases were asymptomatic, 80% (n=4) of gonorrhea cases were asymptomatic, and 100%
(n=3) of syphilis cases were asymptomatic (Figure 4.4). Sites of chlamydia diagnosis were
pharyngeal, rectal, urethral, and vaginal, and four cases involved multiple sites. Sites of gonorrhea
diagnosis were pharyngeal, rectal, and vaginal, and two cases involved multiple sites (Table 4.7).
STI cases were primarily diagnosed on the PrEP intake encounter (62.5%, n=10), followed by asneeded screening (25%, n=4) and the 6-month encounter (12.5%, n=2).
Figure 4. 4. Presence of STI symptom at time of STI diagnosis
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Table 4. 7. Count of chlamydia and gonorrhea diagnosis site and presence of symptom
Site of Diagnosis
Chlamydia
Pharyngeal
Rectal
Urethral
Vaginal
Gonorrhea
Pharyngeal
Rectal
Urethral

n

Total
(%)

Symptomatic
n
(%)

Asymptomatic
n
(%)

2
5
3
2

(16.7)
(41.7)
(25)
(16.7)

0
0
1
2

(0)
(0)
(33.3)
(100)

2
5
2
0

(100)
(100)
(66.7)
(0)

3
3
1

(42.9)
(42.9)
(14.3)

0
0
1

(0)
(0)
(100)

3
3
0

(100)
(100)
(0)
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STI Services in the time of COVID-19
Question 6: How much did NGHD STI testing change in the period associated with the onset of the
COVID-19 pandemic?
STI tests performed by the NGHD declined between the first and second calendar year
quarter (Q1 and Q2) of 2020 as well as between Q2 of 2019 and Q2 of 2020 (Figure 4.5). Between
2020 Q1 and Q2, tests performed for HIV declined by 38% (901 to 561), gonorrhea by 51% (1,595
to 775), chlamydia by 55% (1,588 to 707), and syphilis by 48% (482 to 250). Between 2019 Q2
and 2020 Q2, tests performed for HIV declined by 48% (1,082 to 561), gonorrhea by 64% (2,183
to 775), chlamydia by 68% (2,181 to 707), and syphilis by 55% (551 to 250).
Figure 4. 5. Total NGHD STI tests performed per quarter
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CHAPTER 5
DISCUSSION
Thinking Ethically About PrEP
Question 1: How can the Thinking Ethically framework be used to inform public health
practitioners on PrEP-related decision-making?
The Thinking Ethically framework was designed as an applied model to aid decisionmakers in choosing the best action through multiple ethical approaches. The Thinking Ethically
framework was assessed to determine how it can be used to inform public health practitioners on
PrEP-related decision-making and serve as a useful tool for LHDs deliberating whether to provide
PrEP services. In this study, the Thinking Ethically framework was found to be feasible and
appropriate to evaluate LHD services and provision of PrEP care. Framework theoretical concepts
were presented in a concrete step-by-step process that translated well to public health practice and
the use of multiple ethical approaches (utilitarian, rights, justice, common good, and virtue) was
appropriate to assess the multifactorial impact of PrEP services. The Thinking Ethically framework
can be applied to future PrEP considerations like how to best allocate LHD resources to provide
PrEP services to those most at-risk or whether to provide Long Acting (LA) PrEP once available
given the risks and resource-intensity of LA PrEP compared to currently available oral PrEP
services.
LHD PrEP services were considered to provide a greater net benefit than risks to
stakeholders (utilitarian approach) through the opportunity to prevent HIV, STIs and provide nonHIV services. Services were considered to abide by the rights of most users (rights approach)
although dilemmas remain surrounding privacy and access to PrEP care among minors. Resources
allocated for PrEP (justice approach) facilitated reaching at-risk populations of MSM but did not
adequately reach PWID within the service area. PrEP services were considered to benefit all
members of the community (common good approach) through additional non-HIV services, like
STI prevention and vaccinations. Services were also considered virtuous (virtue approach) by
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targeting vulnerable populations at-risk for HIV although dilemmas remain surrounding stigma of
HIV and STIs in the community.
North Georgia Health District PrEP Services
Question 2: Did NGHD PrEP services reach those most at-risk for HIV in the district?
The NGHD served 63 PrEP users between July 2019 and June 2020 which could be
considered modest enrollment compared to other NGHD programs or PrEP programs in larger
urban centers. The lower NGHD PrEP census was anticipated given the study period assessed the
first year of NGHD PrEP services and the suburban and rural geographic distribution of the NGHD
(which extends from the north Atlanta suburbs into the north Georgia mountains). Suburban and
rural areas can face additional challenges to PrEP awareness and stigma compared to urban centers.
NGHD PrEP services primarily reached the MSM population and PWID were considered to be
largely underrepresented considering two counties in the NGHD service area were previously
identified by the CDC as high-risk for HIV and hepatitis C transmission due to injection drug
use.29,30 Additional resources would be needed for the NGHD to reach and retain PWID in PrEP
care as drug users have faced multiple barriers to care and have been considered a hard-to-reach
population. The predominance of youth in the cohort was consistent with populations identified as
at-risk as youth are generally at higher risk for STIs, and the racial/ethnic distribution of PrEP users
was consistent with the larger population demographics of the service area.
Question 3: How long did PrEP users stay in the program?
Low retention in PrEP care has been documented in the literature and multiple communitybased studies have reported about half of PrEP users discontinued within the first year.18,91 Program
discontinuation may indicate an individual’s reduced risk of HIV or the existence of barriers to
care. Low PrEP program retention supports the need to reduce barriers to PrEP care and continue
other HIV prevention strategies like behavioral change interventions and Treatment as Prevention
(TasP). In this study, 65% of NGHD PrEP users discontinued PrEP within the one-year study
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period and retention in care was found to vary by clinic site. No other demographic factors were
significantly associated with retention in care via negative binomial or logistic regression
modeling. Clinic A had a higher census but lower retention while the other clinic sites had lower
census but higher retention. The discrepancy in retention by clinic site is significant to program
management as variations between clinic sites indicate a need for further exploration for internal
consistency and quality control. Site retention discrepancies could be due to variation in site PrEP
user demographics as Clinic A served more females and those of heterosexual HIV risk compared
to other sites (populations that have been associated with lower retention in PrEP care compared to
MSM).18,85 Discrepancies in clinic site retention could also be due to variation in clinic processes
(program enrollment or follow-up), staff bedside manner, or diversion of resources toward the
COVID-19 pandemic during the study period.
Short retention in PrEP care poses ethical considerations to LHD PrEP program
management including staffing resource distribution and the risk of future LA PrEP provision.
LHDs should consider PrEP retention when distributing staffing resources between multiple
programs as LHDs in suburban and rural areas may not have the PrEP census to justify multiple
dedicated PrEP staff. Conversely, dedicating case-management staff to assist PrEP users facing
psychosocial or administrative barriers to care may benefit program retention. LHDs should also
consider retention in care when deciding whether or not to provide LA PrEP in the future due to the
risk of HIV viral resistance if PrEP is abruptly discontinued and HIV is acquired during the period
of LA PrEP subtherapeutic drug tail.16,77
Question 4: What additional services were provided to PrEP users beyond STI prevention?
Services provided beyond STI prevention were provided to 50.8% of NGHD PrEP users.
Vaccines were the primary additional service provided (45.9%) followed by referrals (29.7%), and
alcohol (13.5%) and smoking cessation counseling (10.8%). LHD provision of PrEP services is
considered an opportunity to engage individuals in holistic preventative care as PrEP users may
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forgo routine services in absence of PrEP use. Referrals provided were primarily to local low-cost
primary care followed by mental health and social services. Referral follow-up was not assessed in
this study and it is unknown how many clients used referral services. The presence of additional
provided services supports that NGHD PrEP users were screened for psychosocial and medical
needs outside of sexual healthcare and attempt to refer individuals to community resources was
made as needed. Providing preventative services to populations at-risk for HIV can benefit both
individual and community wellness.
Question 5: How many asymptomatic bacterial STIs were diagnosed among PrEP users?
Routine NGHD PrEP care includes bacterial STI screening for gonorrhea, chlamydia, and
syphilis to detect asymptomatic STI infection. Previous literature has demonstrated bacterial STI
infection in pharyngeal and rectal sites were more often asymptomatic compared to urethral sites
among MSM populations.23 In this study, 19% of PrEP users were diagnosed with a bacterial STI
during the study period and 75% of bacterial STIs diagnosed were asymptomatic. Chlamydia and
gonorrhea were primarily diagnosed in extra-urethral sites (pharyngeal and rectal), and the majority
(62.5%) of STI cases were diagnosed on the initial PrEP encounter. The rate of asymptomatic STI
diagnosis in this study is higher than previous literature. In a study of 280 PrEP users in New York,
10% of diagnosed STIs were asymptomatic and 11% were diagnosed on the initial PrEP
encounter.59 Results of this study highlight the importance of routine global STI screening of all
exposure sites among PrEP users in the LHD setting.
STI Services in the time of COVID-19
Question 6: How much did NGHD STI testing change in the period associated with the onset of the
COVID-19 pandemic?
The onset of the COVID-19 pandemic impacted NGHD clinical services during the study
period and was therefore considered in the interpretation of study results, but this practice-based
study was not designed or intended to investigate the impact of COVID-19 on LHD PrEP and STI
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care. To encourage social distancing during the pandemic, NGHD LHD sites ceased nonessential
in-person encounters for all programs in the second quarter of 2020. Multiple NGHD clinical sites
providing PrEP care diverted staffing resources toward the pandemic response including COVID19 testing, syndromic surveillance, contact tracing, and vaccination campaigns. Local health
departments, like the NGHD, were (and continue to be at the time of this writing) on the forefront
of the COVID-19 pandemic response.
The total number of STI tests performed by the NGHD from June 2018 to July 2020 was
evaluated to quantify the change in STI services associated with the COVID-19 pandemic and
provide a baseline for leadership to determine when services rebound to pre-pandemic quantity.
Between the first and second calendar year quarter (Q1 and Q2) of 2020, testing for HIV declined
by 38%, gonorrhea by 51%, chlamydia by 55%, and syphilis by 48%. Between 2019 Q2 and 2020
Q2, testing for HIV declined by 48%, gonorrhea by 64%, chlamydia by 68%, and syphilis by 55%.
Gonorrhea and chlamydia testing were correlated as they are generally tested together. The full
impact of COVID-19 on the STI landscape is not yet known, although any reduction in STI
incidence appreciated during the time of the pandemic could be due to a true reduction in STI
incidence due to community social distancing or reduced screening and testing. NGHD STI testing
services also serve as an opportunity to screen individuals for PrEP eligibility, and a reduction in
NGHD STI services is assumed to have impacted enrollment in the PrEP program.
During the period of COVID-19 related clinical service disruption, NGHD PrEP
providers refilled tenofovir/emtricitabine prescriptions if the PrEP user could be contacted by
phone for a verbal adherence and HIV symptom screen. Many NGHD PrEP users also obtained
prescription refills from a mail-order pharmacy in the Ryan White AIDS Drug Assistance Program
(ADAP) pharmacy network. It is reasonable to suspect that PrEP users with reliable phone service
were better able to be retained in care during this time and use of a mail order pharmacy likely
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benefited PrEP users during periods of social distancing, but more research is needed to investigate
retention trends during the COVID-19 pandemic.
Future Research
The COVID-19 pandemic was a significant confounding variable during the study period,
and additional research on the impact of the COVID-19 pandemic on the STI landscape and PrEP
care is needed as the long-term impact of the COVID-19 pandemic on STI trends, LHD fiscal
resources, and resource distribution is not yet known. Follow-up NGHD PrEP program reviews
should also be performed as one year is not enough time to determine long-term trends or impact of
LHD PrEP services. Follow-up program reviews would also benefit from a state-wide evaluation
that includes regional PrEP retention and STI incidence trends from LHD and private providers.
Remaining gaps in the literature include PrEP-related stigma in rural and suburban areas and
reasons for PrEP user discontinuation in suburban and rural LHD settings. Barriers to LHD PrEP
services in rural and suburban areas may differ from urban centers and research on stigma in nonurban LHDs may benefit uptake and provision of rural and suburban PrEP services. Future research
on LA PrEP is needed as LA PrEP is an emerging delivery system and poses additional risk of HIV
viral resistance.16,77 Consideration should also be given to PrEP retention, LA PrEP cost, and
clinical capacity prior to initiating LA PrEP services in the LHD setting.
Limitations
Limitations included the review period of one year after NGHD PrEP service
implementation as one year is not enough time to appreciate long-term effects of PrEP service
delivery. The study did not determine presence of causal relationships between PrEP use and STI
incidence as assessment of temporality or experimental control was not performed. The study only
included NGHD clinic sites and is therefore not a comprehensive assessment of PrEP user
population STI incidence because STIs diagnosed at private, non-NGHD clinics were not included
due to data access limitations. Data obtained in this study was specific to the NGHD (a suburban
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and rural LHD in the Southeast US) and is possibly not generalizable to other settings although
generalizability is not essential for a practice program review to be valuable to LHD practice
program management. The small sample size of the study population and wide confidence interval
of statistical regression results reduces the meaningfulness of point estimates. The retrospective
medical record data may also have some variability in documentation between nurse-provider staff,
and care was taken to select research questions utilizing data that should be consistently present in
the medical record.
Possible confounding variables included PrEP user income and insurance status as these
have been associated with PrEP uptake and retention in PrEP care but were not assessed due to a
lack of available data. The COVID-19 pandemic also occurred during the study period and is
expected to have significantly impacted PrEP provision and STI incidence between March and
June 2020 because the NGHD significantly reduced PrEP and STI service delivery during this time
due to social distancing and redistribution of resources toward COVID-19 public health response.
Obtaining qualitative data from NGHD PrEP provider staff and PrEP users would have been ideal
but could not be performed due to NGHD staffing priorities in response to the ongoing COVID-19
pandemic and risk of COVID-19 exposure to NGHD PrEP users during the time of data collection.
Conclusion
LHDs are critical to the healthcare safety-net, provide key STI prevention services in the
community, and are well-suited to provide PrEP care to those most at-risk for HIV. This practicebased study demonstrated the value of ethical decision-making and practice-based research to LHD
program planning and the need for continuous quality management initiatives in public health
practice. The Thinking Ethically framework adequately elicited potentially conflicting ethical PrEP
considerations and was found to be well-suited to LHD PrEP-related decision-making when
seeking the best course of action. The first year of NGHD PrEP services saw a modest census
compared to urban PrEP programs and study results indicated possible discrepancies in service
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delivery between NGHD study sites. LHD PrEP services were considered an opportunity to screen
for STIs, provide additional health services, and engage vulnerable populations that may otherwise
forgo medical care. The COVID-19 pandemic impacted STI and PrEP service delivery during the
study period and follow-up evaluation is needed as NGHD PrEP census is expected to increase
after the pandemic subsides and the full impact of COVID-19 on program delivery and STI
incidence is not yet known.

80

REFERENCES
1.

Weiss G, Smith DK, Newman S, Wiener J, Kitlas A, Hoover KW. PrEP implementation by local
health departments in US cities and counties: Findings from a 2015 assessment of local health
departments. PLoS ONE. 2018;13(7). doi:10.1371/journal.pone.0200338

2.

Centers for Disease Control and Prevention. US Public Health Service: Preexpoure prophylaxis for
the prevention of HIV infection in the United States -2017 Update: A clinical practice guideline.
Published online March 2018. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines2017.pdf

3.

World Health Organization. WHO/UNAIDS consultation on the ethics of PrEP and early initiation
of ART for prevention. How should countries reach a decision? In: World Health Organization;
2012. Accessed January 31, 2020.
https://apps.who.int/iris/bitstream/handle/10665/112800/9789241507189_eng.pdf;jsessionid=49E
D9A387AA61A62237AB00D65BE364C?sequence=1

4.

Sugarman J, Mayer KH. Ethics and Pre-Exposure Prophylaxis for HIV-infection. J Acquir Immune
Defic Syndr 1999. 2013;63(0 2):S135-S139. doi:10.1097/QAI.0b013e3182987787

5.

Velasquez M, Moberg D, Meyer M, et al. A framework for ethical decision making. Published
online 2015. Accessed May 6, 2020. https://www.scu.edu/ethics/ethics-resources/ethical-decisionmaking/a-framework-for-ethical-decision-making/

6.

Ryan GW, Bloom EW, Lowsky DJ, et al. Innovation Profile: Data-driven decision-making tools to
improve public resource allocation for care and prevention of HIV/AIDS. Health Aff (Millwood).
2014;33(3):410-417. doi:doi: 10.1377/hlthaff.2013.1155

7.

Centers for Disease Control and Prevention. HIV Surveillance Report 2018 (Preliminary). 30:129.

8.

Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure
prophylaxis for all populations. AIDS Lond Engl. 2016;30(12):1973-1983.
doi:10.1097/QAD.0000000000001145

9.

Grant RM, Koester KA. What people want from sex and PrEP. Curr Opin HIV AIDS.
2016;11(1):3-9. doi:10.1097/COH.0000000000000216

10.

Jenness SM, Weiss KM, Goodreau SM, et al. Incidence of Gonorrhea and Chlamydia following
Human Immunodeficiency Virus preexposure prophylaxis among Men Who Have Sex With Men:
A modeling study. Clin Infect Dis. 2017;65(5):712-718. doi:10.1093/cid/cix439

11.

Unemo M, Bradshaw CS, Hocking JS, et al. Sexually transmitted infections: Challenges ahead.
Lancet Infect Dis. 2017;17(8):e235-e279. doi:10.1016/S1473-3099(17)30310-9

12.

Aral SO, Over M, Manhart L, Holmes KK. Sexually Transmitted Infections. In: Jamison DT,
Breman JG, Measham AR, et al., eds. Disease Control Priorities in Developing Countries. 2nd ed.
World Bank; 2006. Accessed January 31, 2020. http://www.ncbi.nlm.nih.gov/books/NBK11734/

13.

Hankins C, Macklin R, Warren M. Translating PrEP effectiveness into public health impact: Key
considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive
justice and advocacy for access. J Int AIDS Soc. 2015;18(4Suppl 3). doi:10.7448/IAS.18.4.19973

81
14.

Stuart RM, Grobicki L, Haghparast‐Bidgoli H, et al. How should HIV resources be allocated?
Lessons learnt from applying Optima HIV in 23 countries. J Int AIDS Soc. 2018;21(4).
doi:10.1002/jia2.25097

15.

Siegler AJ, Mouhanna F, Giler RM, et al. The prevalence of pre-exposure prophylaxis use and the
pre-exposure prophylaxis–to-need ratio in the fourth quarter of 2017, United States. Ann
Epidemiol. 2018;28(12):841-849. doi:10.1016/j.annepidem.2018.06.005

16.

Landovitz RJ, Kofron R, McCauley M. The promise and pitfalls of Long Acting injectable agents
for HIV prevention. Curr Opin HIV AIDS. 2016;11(1):122-128.
doi:10.1097/COH.0000000000000219

17.

Grippo J, Smallwood S, Pincura K, Wright T, Mase W. Physician attitudes toward the ethics of
Pre-exposure Prophylaxis (PrEP): Cost, safety, and resource allocation. J Ga Public Health Assoc.
2017;7(1). doi:10.21633/jgpha.7.104

18.

Coy KC, Hazen RJ, Kirkham HS, Delpino A, Siegler AJ. Persistence on HIV preexposure
prophylaxis medication over a 2‐year period among a national sample of 7148 PrEP users, United
States, 2015 to 2017. J Int AIDS Soc. 2019;22(2). doi:10.1002/jia2.25252

19.

Lee LM. Public health ethics theory: Review and path to convergence. J Law Med Ethics.
2012;40(1):85. doi:10.1111/j.1748-720X.2012.00648.x.

20.

Kass NE. Public health ethics: From foundations and frameworks to justice and global public
health. J Law Med Ethics. 2004;32(2):232-242. doi:10.1111/j.1748-720x.2004.tb00470.x

21.

Soriano V, del Romero J. Rebound in Sexually Transmitted Infections following the success of
antiretrovirals for HIV/AIDS. AIDS Rev. 2018;20(4):187-204. doi:10.24875/AIDSRev.18000034

22.

World Health Organization. Sexually transmitted infections (STIs). Accessed February 21, 2020.
https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis)

23.

Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2018.
Published online 2019:176. doi:10.15620/cdc.79370

24.

Danforth K, Granich R, Wiedeman D, Baxi S, Padian N. Global Mortality and Morbidity of
HIV/AIDS. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, eds. Major Infectious Diseases. 3rd ed.
The International Bank for Reconstruction and Development / The World Bank; 2017. Accessed
April 25, 2020. http://www.ncbi.nlm.nih.gov/books/NBK525184/

25.

Wandeler G, Johnson LF, Egger M. Trends in life expectancy of HIV-positive adults on ART
across the globe: comparisons with general population. Curr Opin HIV AIDS. 2016;11(5):492-500.
doi:10.1097/COH.0000000000000298

26.

Holmes CB, Hallett TB, Walensky RP, Bärnighausen T, Pillay Y, Cohen MS. Effectiveness and
Cost-Effectiveness of Treatment as Prevention for HIV. In: Holmes KK, Bertozzi S, Bloom BR,
Jha P, eds. Major Infectious Diseases. 3rd ed. The International Bank for Reconstruction and
Development / The World Bank; 2017. Accessed April 25, 2020.
http://www.ncbi.nlm.nih.gov/books/NBK525180/

82
27.

U.S. Department of Health and Human Services. Ending the HIV Epidemic: A Plan for America.
Published online February 2020. https://files.hiv.gov/s3fs-public/ending-the-hiv-epidemicflyer.pdf

28.

Georgia Department of Public Health HES. HIV Surveillance Summary, Georgia 2017.; 2019.
https://dph.georgia.gov/data-fact-sheet-summaries

29.

Van Handel MM, Rose CE, Hallisey EJ, et al. County-level vulnerability assessment for rapid
dissemination of HIV or HCV infections among Persons who Inject Drugs, United States Supplemental appendix. J Acquir Immune Defic Syndr 1999. 2016;73(3):323-331.
doi:10.1097/QAI.0000000000001098

30.

Van Handel MM, Rose CE, Hallisey EJ, et al. County-level vulnerability assessment for rapid
dissemination of HIV or HCV infections among Persons who Inject Drugs, United States. J Acquir
Immune Defic Syndr 1999. 2016;73(3):323-331. doi:10.1097/QAI.0000000000001098

31.

Sharpe TT, Harrison KM, Dean HD. Summary of CDC consultation to address social determinants
of health for prevention of Disparities in HIV/AIDS, Viral Hepatitis, Sexually Transmitted
Diseases, and Tuberculosis. Public Health Rep. 2010;125(4_suppl):11-15.
doi:10.1177/00333549101250S404

32.

Dean HD, Fenton KA. Integrating a social determinants of health approach into public health
practice: A five-year perspective of actions implemented by CDC’s National Center for
HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Public Health Rep. 2013;128(Suppl 3):5-11.

33.

Wilson PA, Nanin J, Amesty S, Wallace S, Cherenack EM, Fullilove R. Using Syndemic Theory
to understand vulnerability to HIV infection among Black and Latino Men in New York City. J
Urban Health. 2014;91(5):983-998. doi:10.1007/s11524-014-9895-2

34.

German D, Latkin CA. Social stability and HIV risk behavior: Evaluating the role of accumulated
vulnerability. AIDS Behav. 2012;16(1):168-178. doi:10.1007/s10461-011-9882-5

35.

Du P, McNutt L-A, O’Campo P, Coles FB. Changes in community socioeconomic status and
racial distribution associated with Gonorrhea rates: An analysis at the community level. Sex
Transm Dis. 2009;36(7):430-438. doi:10.1097/OLQ.0b013e31819b8c2f

36.

Nuttbrock L, Bockting W, Rosenblum A, et al. Gender abuse, depressive symptoms, and HIV and
other Sexually Transmitted Infections among Male-to-Female Transgender Persons: A three-year
prospective study. Am J Public Health. 2013;103(2):300-307. doi:10.2105/AJPH.2011.300568

37.

Acheampong AB, Striley CW, Cottler LB. Prescription opioid use, illicit drug use, and sexually
transmitted infections among participants from a community engagement program in North
Central Florida. J Subst Use. 2017;22(1):90-95. doi:10.3109/14659891.2016.1144805

38.

Centers for Disease Control and Prevention. Annual Surveillance Report Of Drug-related Risks
And Outcomes. Published online 2019:128.

39.

Bryan AD, Magnan RE, Gillman AS, et al. Effect of including alcohol and cannabis content in a
sexual risk-reduction intervention on the incidence of Sexually Transmitted Infections in
adolescents. JAMA Pediatr. 2018;172(4). doi:10.1001/jamapediatrics.2017.5621

83
40.

Brooks A, Meade CS, Potter JS, Lokhnygina Y, Calsyn DA, Greenfield SF. Gender differences in
the rates and correlates of HIV risk behaviors among drug abusers. Subst Use Misuse.
2010;45(14):2444-2469. doi:10.3109/10826084.2010.490928

41.

Chiasson MA, Hirshfield S, Humberstone M, Difilippi J, Koblin BA, Remien RH. Increased high
risk sexual behavior after September 11 in men who have sex with men: An internet survey. Arch
Sex Behav. 2005;34(5):527-535. doi:doi: 10.1007/s10508-005-6278-5

42.

Vlahov D, Galea S, Ahern J, Resnick H, Kilpatrick D. Sustained increased consumption of
cigarettes, alcohol, and marijuana among Manhattan residents after september 11, 2001. Am J
Public Health. 2004;94(2):253-254. doi:10.2105/ajph.94.2.253

43.

Angeles Perez-Morente M, Teresa Sanchez-Ocon M, Martinez-Garcia E, Martin-Salvador A,
Hueso-Montoro C, Garcia-Garcia I. Differences in Sexually Transmitted Infections between the
Precrisis Period (2000-2007) and the Crisis Period (2008-2014) in Granada, Spain. J Clin Med.
2019;8(2). doi:10.3390/jcm8020277

44.

Suhrcke M, Stuckler D, Suk JE, et al. The impact of economic crises on communicable disease
transmission and control: A systematic review of the evidence. PLoS ONE. 2011;6(6):1-12.
doi:10.1371/journal.pone.0020724

45.

Walker M. COVID-19 Upended HIV Prevention Efforts at Boston Clinic. Published July 6, 2020.
Accessed July 7, 2020. https://www.medpagetoday.com/meetingcoverage/iac/87423

46.

Sanchez TH, Zlotorzynska M, Rai M, Baral SD. Characterizing the Impact of COVID-19 on Men
Who Have Sex with Men Across the United States in April, 2020. AIDS Behav. 2020;24(7):20242032. doi:10.1007/s10461-020-02894-2

47.

Halkitis PN, Kutnick AH, Rosof E, Slater S, Parsons JT. Adherence to HIV medications in a
cohort of Men Who Have Sex With Men: Impact of September 11th. J Urban Health Bull N Y
Acad Med. 2003;80(1):161-166. doi:10.1093/jurban/jtg161

48.

Ibragimov U, Beane S, Friedman SR, et al. States with higher minimum wages have lower STI
rates among women: Results of an ecological study of 66 US metropolitan areas, 2003-2015. PLoS
ONE. 2019;14(10). doi:10.1371/journal.pone.0223579

49.

Mann JR, Stine CC, Vessey J. The role of disease-specific infectivity and number of disease
exposures on long-term effectiveness of the latex condom. Sex Transm Dis. 2002;29(6):344-349.
doi:10.1097/00007435-200206000-00006

50.

Steiner MJ, Cates W, Warner L. The real problem with male condoms Is nonuse. Sex Transm Dis.
1999;26(8):459-462. doi:10.1097/00007435-199909000-00007

51.

Siegler AJ, Rosenthal EM, Sullivan PS, et al. Levels of clinical condom failure for anal sex: A
randomized cross-over trial. EClinicalMedicine. 2019;17. doi:10.1016/j.eclinm.2019.10.012

52.

Cohen D, Scribner R, Bedimo R, Farley TA. Cost as a barrier to condom use: The evidence for
condom subsidies in the United States. Am J Public Health. 1999;89(4):567-568.
doi:10.2105/ajph.89.4.567

84
53.

Charania MR, Crepaz N, Guenther-Gray C, et al. Efficacy of structural-level condom distribution
interventions: A meta-analysis of U.S. and international studies, 1998–2007. AIDS Behav.
2011;15(7):1283-1297. doi:10.1007/s10461-010-9812-y

54.

McCool-Myers M, Myo A, Carter JA. Barriers to purchasing condoms in a high HIV/STI-risk
urban area. J Community Health. 2019;44(4):836-843. doi:10.1007/s10900-019-00670-5

55.

Albarracín D, Gillette JC, Earl AN, Glasman LR, Durantini MR, Ho M-H. A test of major
assumptions about behavior change: A comprehensive look at the effects of passive and active
HIV-prevention interventions since the beginning of the epidemic. Psychol Bull. 2005;131(6):856897. doi:10.1037/0033-2909.131.6.856

56.

Huebner DM, Perry NS. Do behavioral scientists really understand HIV-related sexual risk
behavior? A systematic review of longitudinal and experimental studies predicting sexual
behavior. Arch Sex Behav. 2015;44(7):1915-1936. doi:10.1007/s10508-015-0482-8

57.

Montaño MA, Dombrowski JC, Dasgupta S, et al. Changes in sexual behavior and STI diagnoses
among MSM initiating PrEP in a clinic setting. AIDS Behav. 2019;23(2):548-555.
doi:10.1007/s10461-018-2252-9

58.

Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV
Preexposure Prophylaxis in a clinical practice setting. Clin Infect Dis Off Publ Infect Dis Soc Am.
2015;61(10):1601-1603. doi:10.1093/cid/civ778

59.

Golub S, Pena S, Boonrai K, Douglas N, Hunt M, Radix A. STI data from community-based PrEP
implementation suggest changes to CDC guidelines. Presented at the: Conference on Retroviruses
and Opportunistic Infections; February 2016; Boston, MA. Accessed July 7, 2020.
https://www.croiconference.org/abstract/sti-data-community-based-prep-implementation-suggestchanges-cdc-guidelines-0/

60.

Huebner DM, Rebchook GM, Kegeles SM. A longitudinal study of the association between
treatment optimism and sexual risk behavior in young adult gay and bisexual men. JAIDS J Acquir
Immune Defic Syndr. 2004;37(4):1514-1519. doi:10.1097/01.qai.0000127027.55052.22

61.

Freeborn K, Portillo CJ. Does pre-exposure prophylaxis for HIV prevention in men who have sex
with men change risk behaviour? A systematic review. J Clin Nurs. 2018;27(17-18):3254-3265.
doi:10.1111/jocn.13990

62.

Rojas Castro D, Delabre RM, Molina J. Give PrEP a chance: Moving on from the “risk
compensation” concept. J Int AIDS Soc. 2019;22:N.PAG-N.PAG. doi:10.1002/jia2.25351

63.

Collins S, McMahan V, Stekler J. The impact of HIV Pre-exposure Prophylaxis (PrEP) use on the
sexual health of Men Who Have Sex with Men: A qualitative study in Seattle, WA.
doi:10.1080/19317611.2016.1206051

64.

Storholm ED, Volk JE, Marcus JL, Silverberg MJ, Satre DD. Risk perception, sexual behaviors,
and PrEP adherence among substance-using men who have sex with men: A qualitative study.
Prev Sci Off J Soc Prev Res. 2017;18(6):737-747. doi:10.1007/s11121-017-0799-8

85
65.

Stanger-Hall KF, Hall DW. Abstinence-only education and teen pregnancy rates: Why we need
comprehensive sex education in the U.S. PLoS ONE. 2011;6(10).
doi:10.1371/journal.pone.0024658

66.

Chin HB, Sipe TA, Elder R, et al. The effectiveness of group-based comprehensive risk-reduction
and abstinence education interventions to prevent or reduce the risk of adolescent pregnancy,
Human Immunodeficiency Virus, and Sexually Transmitted Infections. Am J Prev Med.
2012;42(3):272-294. doi:10.1016/j.amepre.2011.11.006

67.

Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 Infection with early antiretroviral
therapy. N Engl J Med. 2011;365(6):493-505. doi:10.1056/NEJMoa1105243

68.

Centers for Disease Control and Prevention. TasP Technical Fact Sheet. Published online 2018.
Accessed February 24, 2020. https://www.cdc.gov/hiv/pdf/risk/art/cdc-hiv-art-viralsuppression.pdf

69.

Mayer K, Gazzard B, Zuniga JM, et al. Controlling the HIV epidemic with antiretrovirals: IAPAC
consensus statement on Treatment as Prevention and Preexposure Prophylaxis. J Int Assoc Provid
AIDS Care JIAPAC. 2013;12(3):208-216. doi:10.1177/2325957413475839

70.

U.S. Department of Health and Human Services. The Stages of HIV Infection Understanding
HIV/AIDS. AIDSinfo. Published June 25, 2019. Accessed April 26, 2020.
https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/19/46/the-stages-of-hiv-infection

71.

Mandsager P, Marier A, Cohen S, Fanning M, Hauck H, Cheever LW. Reducing HIV-related
health disparities in the Health Resources and Services Administration’s Ryan White HIV/AIDS
Program. Am J Public Health. 2018;108:S246-S250. doi:10.2105/AJPH.2018.304689

72.

Barnhart M. Long-Acting HIV treatment and prevention: Closer to the threshold. Glob Health Sci
Pract. 2017;5(2):182-187. doi:10.9745/GHSP-D-17-00206

73.

U.S. Department of Health and Human Services. Pre-Exposure Prophylaxis. HIV.gov. Published
December 3, 2019. Accessed August 23, 2020. https://www.hiv.gov/hiv-basics/hivprevention/using-hiv-medication-to-reduce-risk/pre-exposure-prophylaxis

74.

World Health Organization. What’s the 2+1+1? Event-Driven Oral Pre-Exposure Prophylaxis to
Prevent HIV for Men Who Have Sex with Men: Update to WHO’s Recommendation on Oral
PrEP.; 2019. Accessed March 14, 2020.
https://apps.who.int/iris/bitstream/handle/10665/325955/WHO-CDS-HIV-19.8-eng.pdf?ua=1

75.

Centers for Disease Control and Prevention. 2017 Hepatitis Surveillance Report. Accessed April 5,
2020. https://www.cdc.gov/hepatitis/statistics/2017surveillance/pdfs/2017HepSurveillanceRpt.pdf

76.

Markowitz M, Grossman H, Anderson PL, et al. Newly acquired infection with multidrug-resistant
HIV-1 in a patient adherent to Preexposure Prophylaxis. JAIDS J Acquir Immune Defic Syndr.
2017;76(4):e104. doi:10.1097/QAI.0000000000001534

77.

Radzio-Basu J, Council O, Cong M, et al. Drug resistance emergence in macaques administered
cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection. Nat Commun.
2019;10. doi:10.1038/s41467-019-10047-w

86
78.

U.S. Department of Health and Human Services. What to Start Adult and Adolescent ARV.
AIDSinfo. Published December 18, 2019. Accessed April 5, 2020.
https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/11/what-to-start

79.

Underhill K. Intimacy, condom use, and Pre-Exposure Prophylaxis (PrEP) acceptability among
men who have sex with men (MSM) in primary partnerships: A comment on Gamarel and Golub.
Ann Behav Med Publ Soc Behav Med. 2015;49(2):151-153. doi:10.1007/s12160-014-9651-6

80.

Smith DK, Van Handel M, Grey J. Estimates of adults with indications for HIV pre-exposure
prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. Ann
Epidemiol. 2018;28(12):850-857.e9. doi:10.1016/j.annepidem.2018.05.003

81.

Pinto RM, Berringer KR, Melendez R, Mmeje O. Improving PrEP implementation through
multilevel interventions: A synthesis of the literature. AIDS Behav. 2018;22(11):3681-3691.
doi:10.1007/s10461-018-2184-4

82.

Elion R, Coleman M. The preexposure prophylaxis revolution: From clinical trials to routine
practice: Implementation view from the USA. Curr Opin HIV AIDS. 2016;11(1):67-73.
doi:10.1097/COH.0000000000000222

83.

Siegler AJ, Bratcher A, Weiss KM. Geographic access to Preexposure Prophylaxis clinics among
men who have sex with men in the United States. Am J Public Health. 2019;109(9):1216-1223.

84.

Biello KB, Bazzi AR, Mimiaga MJ, et al. Perspectives on HIV pre-exposure prophylaxis (PrEP)
utilization and related intervention needs among people who inject drugs. Harm Reduct J.
2018;15. doi:10.1186/s12954-018-0263-5

85.

Cahill S, Taylor SW, Elsesser SA, Mena L, Hickson D, Mayer KH. Stigma, medical mistrust, and
perceived racism may affect PrEP awareness and uptake in black compared to white gay and
bisexual men in Jackson, Mississippi and Boston, Massachusetts. AIDS Care. 2017;29(11):13511358. doi:10.1080/09540121.2017.1300633

86.

Paparini S, Nutland W, Rhodes T, Nguyen V-K, Anderson J. DIY HIV prevention: Formative
qualitative research with men who have sex with men who source PrEP outside of clinical trials.
PLoS ONE. 2018;13(8). doi:10.1371/journal.pone.0202830

87.

Horberg M, Raymond B. Financial policy issues for HIV Pre-Exposure Prophylaxis: Cost and
access to insurance. Am J Prev Med. 2013;44(1, Supplement 2):S125-S128.
doi:10.1016/j.amepre.2012.09.039

88.

Smith DK, Van Handel M, Huggins R. Estimated Coverage to Address Financial Barriers to HIV
Preexposure Prophylaxis Among Persons With Indications for Its Use, United States, 2015: JAIDS
J Acquir Immune Defic Syndr. 2017;76(5):465-472. doi:10.1097/QAI.0000000000001532

89.

Koss CA, Hosek SG, Bacchetti P, et al. Comparison of aeasures of adherence to Human
Immunodeficiency Virus Preexposure Prophylaxis among adolescent and young men who have
sex with men in the United States. Clin Infect Dis. 2018;66(2):213-219. doi:10.1093/cid/cix755

90.

John SA, Whitfield THF, Rendina HJ, Parsons JT, Grov C. Why I quit Pre-Exposure Prophylaxis
(PrEP)? A mixed-method study exploring reasons for PrEP discontinuation and potential re-

87
initiation among gay and bisexual men. AIDS Behav. 2018;22(11):3566-3575.
doi:10.1007/s10461-018-2045-1
91.

Lankowski AJ, Bien-Gund CH, Patel VV, Felsen UR, Silvera R, Blackstock OJ. PrEP in the Real
World: Predictors of 6-Month Retention in a Diverse Urban Cohort. AIDS Behav.
2019;23(7):1797-1802. doi:10.1007/s10461-018-2296-x

92.

Underhill K, Guthrie KM, Colleran C, Calabrese SK, Operario D, Mayer KH. Temporal
fluctuations in behavior, perceived HIV risk, and willingness to use Pre-Exposure Prophylaxis
(PrEP). Arch Sex Behav. 2018;47(7):2109-2121. doi:10.1007/s10508-017-1100-8

93.

Elsesser SA, Oldenburg CE, Biello KB, et al. Seasons of risk: anticipated behavior on vacation and
interest in episodic antiretroviral Pre-Exposure Prophylaxis (PrEP) among a large national sample
of U.S. men who have sex with men (MSM). AIDS Behav. 2016;20(7):1400-1407.
doi:10.1007/s10461-015-1238-0

94.

Namey E, Agot K, Ahmed K, et al. When and why women might suspend PrEP use according to
perceived seasons of risk: implications for PrEP-specific risk-reduction counselling. Cult Health
Sex. 2016;18(9):1081-1091. doi:10.1080/13691058.2016.1164899

95.

Dubov A, Altice FL, Fraenkel L. An Information–Motivation–Behavioral Skills model of PrEP
uptake. AIDS Behav. 2018;22(11):3603-3616. doi:10.1007/s10461-018-2095-4

96.

Trent-Adams S, Cheever LW. Providing HIV Pre-Exposure Prophylaxis: Lessons learned from the
Ryan White HIV/AIDS Program. Am J Prev Med. 2013;44(1, Supplement 2):S147-S150.
doi:10.1016/j.amepre.2012.09.031

97.

Bernard CL, Brandeau ML, Humphreys K, et al. Cost-effectiveness of HIV Preexposure
Prophylaxis for people who inject drugs in the United States. Ann Intern Med. Published online
April 26, 2016. doi:10.7326/M15-2634

98.

Juusola JL, Brandeau ML. HIV treatment and prevention: A aimple model to determine optimal
investment. Med Decis Making. 2016;36(3):391-409. doi:10.1177/0272989X15598528

99.

National Alliance of State and Territorial AIDS Directors. NASTAD PrEP financing models chart.
Published online 2018. Accessed May 5, 2020.
https://www.nastad.org/sites/default/files/nastad_prep_financing_models_chart_8.1.16.pdf

100.

Smith DK, Van Handel M, Huggins R. Estimated coverage to address financial barriers to HIV
Preexposure Prophylaxis among persons with indications for its use, United States, 2015. JAIDS J
Acquir Immune Defic Syndr. 2017;76(5):465-472. doi:10.1097/QAI.0000000000001532

101.

Leichliter JS, Heyer K, Peterman TA, et al. U.S. public STD clinical services in an era of declining
public health funding: 2013–14. Sex Transm Dis. 2017;44(8):505-509.
doi:10.1097/OLQ.0000000000000629

102.

Sukhija-Cohen AC, Beymer MR, Engeran-Cordova W, Bolan RK. From control to crisis: The
resurgence of Sexually Transmitted Diseases. Sex Transm Dis. 2019;46(2):e8-e10.
doi:10.1097/OLQ.0000000000000960

88
103.

Myers JE, Edelstein ZR, Daskalakis DC, et al. Preexposure Prophylaxis monitoring in New York
City: A public health approach. Am J Public Health. 2018;108:S251-S257.
doi:10.2105/AJPH.2018.304729

104.

Zhang HL, Rhea SK, Hurt CB, et al. HIV pre-exposure prophylaxis implementation at local health
departments: A statewide assessment of activities and barriers. J Acquir Immune Defic Syndr 1999.
2018;77(1):72-77. doi:10.1097/QAI.0000000000001546

105.

Georgia Department of Public Health. Georgia Integrated HIV Prevention and Care Plan 20172021. Accessed May 6, 2020. https://dph.georgia.gov/health-topics/office-hivaids

106.

WHO Implementation Tool for Pre-Exposure Prophylaxis (PrEP) of HIV Infection. World Health
Organization; 2018. Accessed July 7, 2020.
https://apps.who.int/iris/bitstream/handle/10665/279834/WHO-CDS-HIV-18.10-eng.pdf?ua=1

107.

Centers for Disease Control and Prevention. Preexposure Prophylaxis for the Prevention of HIV
Infeciton in the United States - 2017 Update Clinical Provider’s Supplement. US Public Health
Service; 2018. Accessed July 8, 2020. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prepprovider-supplement-2017.pdf

108.

Parisi D, Warren B, Leung SJ, et al. A Multicomponent Approach to Evaluating a Pre-exposure
Prophylaxis (PrEP) Implementation Program in Five Agencies in New York. J Assoc Nurses AIDS
Care JANAC. 2018;29(1):10-19. doi:10.1016/j.jana.2017.06.006

89

APPENDIX
INSTITUTIONAL REVIEW BOARD APPROVAL FORM

